1
|
Villarroya‐Beltri C, Martins AFB, García A, Giménez D, Zarzuela E, Novo M, del Álamo C, González‐Martínez J, Bonel‐Pérez GC, Díaz I, Guillamot M, Chiesa M, Losada A, Graña‐Castro O, Rovira M, Muñoz J, Salazar‐Roa M, Malumbres M. Mammalian CDC14 phosphatases control exit from stemness in pluripotent cells. EMBO J 2023; 42:e111251. [PMID: 36326833 PMCID: PMC9811616 DOI: 10.15252/embj.2022111251] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/23/2022] [Revised: 10/17/2022] [Accepted: 10/18/2022] [Indexed: 11/06/2022] Open
Abstract
Maintenance of stemness is tightly linked to cell cycle regulation through protein phosphorylation by cyclin-dependent kinases (CDKs). However, how this process is reversed during differentiation is unknown. We report here that exit from stemness and differentiation of pluripotent cells along the neural lineage are controlled by CDC14, a CDK-counteracting phosphatase whose function in mammals remains obscure. Lack of the two CDC14 family members, CDC14A and CDC14B, results in deficient development of the neural system in the mouse and impairs neural differentiation from embryonic stem cells (ESCs). Mechanistically, CDC14 directly dephosphorylates specific proline-directed Ser/Thr residues of undifferentiated embryonic transcription Factor 1 (UTF1) during the exit from stemness, triggering its proteasome-dependent degradation. Multiomic single-cell analysis of transcription and chromatin accessibility in differentiating ESCs suggests that increased UTF1 levels in the absence of CDC14 prevent the proper firing of bivalent promoters required for differentiation. CDC14 phosphatases are dispensable for mitotic exit, suggesting that CDC14 phosphatases have evolved to control stemness rather than cell cycle exit and establish the CDK-CDC14 axis as a critical molecular switch for linking cell cycle regulation and self-renewal.
Collapse
Affiliation(s)
| | - Ana Filipa B Martins
- Cell Division and Cancer groupSpanish National Cancer Research Centre (CNIO)MadridSpain
| | - Alejandro García
- Cell Division and Cancer groupSpanish National Cancer Research Centre (CNIO)MadridSpain
| | | | | | - Mónica Novo
- Cell Division and Cancer groupSpanish National Cancer Research Centre (CNIO)MadridSpain
| | - Cristina del Álamo
- Cell Division and Cancer groupSpanish National Cancer Research Centre (CNIO)MadridSpain
| | | | - Gloria C Bonel‐Pérez
- Cell Division and Cancer groupSpanish National Cancer Research Centre (CNIO)MadridSpain
| | - Irene Díaz
- Cell Division and Cancer groupSpanish National Cancer Research Centre (CNIO)MadridSpain
| | - María Guillamot
- Cell Division and Cancer groupSpanish National Cancer Research Centre (CNIO)MadridSpain
| | - Massimo Chiesa
- Cell Division and Cancer groupSpanish National Cancer Research Centre (CNIO)MadridSpain
| | - Ana Losada
- Chromosome Dynamics groupCNIOMadridSpain
| | - Osvaldo Graña‐Castro
- Bioinformatics UnitCNIOMadridSpain
- Present address:
Department of Basic Medical Sciences, Institute of Applied Molecular Medicine (IMMA‐Nemesio Díez), School of MedicineSan Pablo‐CEU University, CEU UniversitiesBoadilla del MonteSpain
| | - Meritxell Rovira
- Department of Physiological Science, School of Medicine, L'Hospitalet de LlobregatUniversity of Barcelona (UB)BarcelonaSpain
- Pancreas Regeneration: Pancreatic Progenitors and Their Niche Group, Regenerative Medicine Program, P‐CMR[C]Institut d'Investigació Biomèdica de Bellvitge—IDIBELL, L'Hospitalet de LlobregatBarcelonaSpain
| | | | - María Salazar‐Roa
- Cell Division and Cancer groupSpanish National Cancer Research Centre (CNIO)MadridSpain
- Present address:
Advanced Therapies and Cancer Group, Faculty of BiologyComplutense UniversityMadridSpain
| | - Marcos Malumbres
- Cell Division and Cancer groupSpanish National Cancer Research Centre (CNIO)MadridSpain
| |
Collapse
|
2
|
de la Cruz-Merino L, Gion M, Cruz J, Alonso-Romero JL, Quiroga V, Moreno F, Andrés R, Santisteban M, Ramos M, Holgado E, Cortés J, López-Miranda E, Cortés A, Henao F, Palazón-Carrión N, Rodriguez LM, Ceballos I, Soto A, Puertes A, Casas M, Benito S, Chiesa M, Bezares S, Caballero R, Jiménez-Cortegana C, Sánchez-Margalet V, Rojo F. Pembrolizumab in combination with gemcitabine for patients with HER2-negative advanced breast cancer: GEICAM/2015-04 (PANGEA-Breast) study. BMC Cancer 2022; 22:1258. [PMID: 36463104 PMCID: PMC9719636 DOI: 10.1186/s12885-022-10363-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/22/2022] [Accepted: 11/24/2022] [Indexed: 12/04/2022] Open
Abstract
BACKGROUND We evaluated a new chemoimmunotherapy combination based on the anti-PD1 monoclonal antibody pembrolizumab and the pyrimidine antimetabolite gemcitabine in HER2- advanced breast cancer (ABC) patients previously treated in the advanced setting, in order to explore a potential synergism that could eventually obtain long term benefit in these patients. METHODS HER2-negative ABC patients received 21-day cycles of pembrolizumab 200 mg (day 1) and gemcitabine (days 1 and 8). A run-in-phase (6 + 6 design) was planned with two dose levels (DL) of gemcitabine (1,250 mg/m2 [DL0]; 1,000 mg/m2 [DL1]) to determine the recommended phase II dose (RP2D). The primary objective was objective response rate (ORR). Tumor infiltrating lymphocytes (TILs) density and PD-L1 expression in tumors and myeloid-derived suppressor cells (MDSCs) levels in peripheral blood were analyzed. RESULTS Fourteen patients were treated with DL0, resulting in RP2D. Thirty-six patients were evaluated during the first stage of Simon's design. Recruitment was stopped as statistical assumptions were not met. The median age was 52; 21 (58%) patients had triple-negative disease, 28 (78%) visceral involvement, and 27 (75%) ≥ 2 metastatic locations. Progression disease was observed in 29 patients. ORR was 15% (95% CI, 5-32). Eight patients were treated ≥ 6 months before progression. Fourteen patients reported grade ≥ 3 treatment-related adverse events. Due to the small sample size, we did not find any clear association between immune tumor biomarkers and treatment efficacy that could identify a subgroup with higher probability of response or better survival. However, patients that experienced a clinical benefit showed decreased MDSCs levels in peripheral blood along the treatment. CONCLUSION Pembrolizumab 200 mg and gemcitabine 1,250 mg/m2 were considered as RP2D. The objective of ORR was not met; however, 22% patients were on treatment for ≥ 6 months. ABC patients that could benefit of chemoimmunotherapy strategies must be carefully selected by robust and validated biomarkers. In our heavily pretreated population, TILs, PD-L1 expression and MDSCs levels could not identify a subgroup of patients for whom the combination of gemcitabine and pembrolizumab would induce long term benefit. TRIAL REGISTRATION ClinicalTrials.gov and EudraCT (NCT03025880 and 2016-001,779-54, respectively). Registration dates: 20/01/2017 and 18/11/2016, respectively.
Collapse
Affiliation(s)
- L. de la Cruz-Merino
- grid.411375.50000 0004 1768 164XDepartment of Medical Oncology, Medicine Department, Virgen Macarena University Hospital, University of Seville, Dr. Fedriani St, No. 3, Seville, 41009 Spain ,grid.430580.aGEICAM Spanish Breast Cancer Group, San Sebastián de los Reyes, Madrid, Spain
| | - M. Gion
- grid.430580.aGEICAM Spanish Breast Cancer Group, San Sebastián de los Reyes, Madrid, Spain ,grid.411347.40000 0000 9248 5770Department of Medical Oncology, Hospital Universitario Ramón y Cajal, Madrid, Spain
| | - J. Cruz
- grid.430580.aGEICAM Spanish Breast Cancer Group, San Sebastián de los Reyes, Madrid, Spain ,grid.411220.40000 0000 9826 9219Department of Medical Oncology, Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain
| | - JL. Alonso-Romero
- grid.430580.aGEICAM Spanish Breast Cancer Group, San Sebastián de los Reyes, Madrid, Spain ,grid.411372.20000 0001 0534 3000Department of Medical Oncology, Hospital Clínico Universitario Virgen de La Arrixaca-IMIB, Murcia, Spain
| | - V. Quiroga
- grid.430580.aGEICAM Spanish Breast Cancer Group, San Sebastián de los Reyes, Madrid, Spain ,grid.418701.b0000 0001 2097 8389Department of Medical Oncology, Badalona Applied Research Group in Oncology (B-ARGO Group), Catalan Institute of Oncology, Badalona, Spain
| | - F. Moreno
- grid.430580.aGEICAM Spanish Breast Cancer Group, San Sebastián de los Reyes, Madrid, Spain ,grid.411068.a0000 0001 0671 5785Department of Medical Oncology, Hospital Clínico Universitario San Carlos, Madrid, Spain
| | - R. Andrés
- grid.430580.aGEICAM Spanish Breast Cancer Group, San Sebastián de los Reyes, Madrid, Spain ,grid.411050.10000 0004 1767 4212Department of Medical Oncology, Hospital Clínico Universitario Lozano Blesa, Saragossa, Spain
| | - M. Santisteban
- grid.430580.aGEICAM Spanish Breast Cancer Group, San Sebastián de los Reyes, Madrid, Spain ,grid.411730.00000 0001 2191 685XDepartment of Medical Oncology, Clínica Universidad de Navarra, Navarra, Spain ,grid.508840.10000 0004 7662 6114IdiSNA, Navarra Institute for Health Research, Pamplona, Spain
| | - M. Ramos
- grid.430580.aGEICAM Spanish Breast Cancer Group, San Sebastián de los Reyes, Madrid, Spain ,grid.418394.3Department of Medical Oncology, Centro Oncológico de Galicia, A Coruña, Spain
| | - E. Holgado
- grid.430580.aGEICAM Spanish Breast Cancer Group, San Sebastián de los Reyes, Madrid, Spain ,grid.414808.10000 0004 1772 3571Department of Medical Oncology, Hospital La Luz, Quironsalud, Madrid, Spain
| | - J. Cortés
- grid.430580.aGEICAM Spanish Breast Cancer Group, San Sebastián de los Reyes, Madrid, Spain ,International Breast Cancer Center (IBCC), Quiron Group, Barcelona and Madrid, Spain ,grid.411083.f0000 0001 0675 8654Vall d´Hebron Institute of Oncology (VHIO), Barcelona, Spain ,grid.119375.80000000121738416Faculty of Biomedical and Health Sciences, Department of Medicine, Universidad Europea de Madrid, Madrid, Spain
| | - E. López-Miranda
- grid.430580.aGEICAM Spanish Breast Cancer Group, San Sebastián de los Reyes, Madrid, Spain ,grid.411347.40000 0000 9248 5770Department of Medical Oncology, Hospital Universitario Ramón y Cajal, Madrid, Spain
| | - A. Cortés
- grid.411347.40000 0000 9248 5770Department of Medical Oncology, Hospital Universitario Ramón y Cajal, Madrid, Spain
| | - F. Henao
- grid.411375.50000 0004 1768 164XDepartment of Medical Oncology, Medicine Department, Virgen Macarena University Hospital, University of Seville, Dr. Fedriani St, No. 3, Seville, 41009 Spain ,grid.430580.aGEICAM Spanish Breast Cancer Group, San Sebastián de los Reyes, Madrid, Spain
| | - N. Palazón-Carrión
- grid.411375.50000 0004 1768 164XDepartment of Medical Oncology, Medicine Department, Virgen Macarena University Hospital, University of Seville, Dr. Fedriani St, No. 3, Seville, 41009 Spain ,grid.430580.aGEICAM Spanish Breast Cancer Group, San Sebastián de los Reyes, Madrid, Spain
| | - L. M. Rodriguez
- grid.430580.aGEICAM Spanish Breast Cancer Group, San Sebastián de los Reyes, Madrid, Spain ,grid.411220.40000 0000 9826 9219Department of Medical Oncology, Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain
| | - I. Ceballos
- grid.430580.aGEICAM Spanish Breast Cancer Group, San Sebastián de los Reyes, Madrid, Spain ,grid.411220.40000 0000 9826 9219Department of Medical Oncology, Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain
| | - A. Soto
- grid.411372.20000 0001 0534 3000Department of Medical Oncology, Hospital Clínico Universitario Virgen de La Arrixaca-IMIB, Murcia, Spain
| | - A. Puertes
- grid.411372.20000 0001 0534 3000Department of Medical Oncology, Hospital Clínico Universitario Virgen de La Arrixaca-IMIB, Murcia, Spain
| | - M. Casas
- grid.430580.aGEICAM Spanish Breast Cancer Group, San Sebastián de los Reyes, Madrid, Spain
| | - S. Benito
- grid.430580.aGEICAM Spanish Breast Cancer Group, San Sebastián de los Reyes, Madrid, Spain
| | - M. Chiesa
- grid.430580.aGEICAM Spanish Breast Cancer Group, San Sebastián de los Reyes, Madrid, Spain
| | - S. Bezares
- grid.430580.aGEICAM Spanish Breast Cancer Group, San Sebastián de los Reyes, Madrid, Spain
| | - R. Caballero
- grid.430580.aGEICAM Spanish Breast Cancer Group, San Sebastián de los Reyes, Madrid, Spain
| | - C. Jiménez-Cortegana
- grid.411375.50000 0004 1768 164XMedical Biochemistry and Molecular Biology and Immunology Department, Virgen Macarena University Hospital, University of Seville, Seville, Spain
| | - V. Sánchez-Margalet
- grid.411375.50000 0004 1768 164XMedical Biochemistry and Molecular Biology and Immunology Department, Virgen Macarena University Hospital, University of Seville, Seville, Spain
| | - F. Rojo
- grid.430580.aGEICAM Spanish Breast Cancer Group, San Sebastián de los Reyes, Madrid, Spain ,grid.419651.e0000 0000 9538 1950Pathology Department, IIS-Fundación Jiménez Díaz, Madrid, Spain ,CIBERONC-ISCIII, Madrid, Spain
| |
Collapse
|
3
|
Conte E, Chiesa M, Mushtaq S, Schillaci M, Marchetti D, Baggiano A, Volpe A, Colombo G, Pompilio G, Bartorelli A, Pontone G, Andreini D. Deep learning applied to facial features for prediction of high risk coronary atherosclerosis at cardiac CT: preliminary data from LOMBROSO Trial. Eur Heart J 2022. [DOI: 10.1093/eurheartj/ehac544.1411] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Background
Cardiac computed tomography (CT) emerged as an accurate tool for non-invasive evaluation of coronary artery disease (CAD), being able to identify high risk non-calcified atherosclerosis. Identification of high risk CAD in its asymptomatic stage could be an interest target for medical therapy. Nowadays no validated tools are available to predict the presence of high risk atherosclerosis, probably due to the multifactorial pathogenesis of atherosclerosis. Facial features may express both genetic and environmental factors that could be associated to high risk atherosclerosis. Aim of the present study was to verify whether deep learning models applied to facial features may accurately predict the presence of high risk coronary atherosclerosis evaluated at cardiac CT
Methods
We enrolled a consecutive cohort of patients who underwent clinical indicated cardiac CT for suspected, CAD. Before CT, 10 facial photos were taken from every patients from random fronts views.
All cardiac CT were analysed for the presence of non-calcified plaque volume (defined as <150 HU at CT); the non-calcified plaque volume was quantified on a per-patient basis in mm3 and a cut off of >23 mm3 was used to define a patients with an elevated volume non-calcified plaque
We built a deep learning model, exploiting the transfer learning technique; briefly, we implemented an “xception” architecture, joining a pre-trained convolutional part with a specific combination of dense layers, in which an output layer follows a hidden layer with 512 neurons and a dropout layer with a dropout rate=0.2. The batch size, the number of epochs and the learning rate were 16, 20, and 0.0001, respectively. A training set composed of 198 face images was fed into the model, while 20 face images served as test set for the prediction of the presence of elevated volume of non-calcified plaque from patients facial features.
Results
We present early results from the first 20 patients enrolled (12 male and 8 female, with mean age of 73±13 years old). In 9 patients cardiac CT resulted completely normal, while in 11 subjects the presence of coronary atherosclerosis was demonstrated. Among them, 9 patients presented non-calcified coronary atherosclerosis, while 6 had an elevated volume of non-calcified plaque.
On the test set, we obtained an accuracy, sensitivity, specificity, positive predictive value, negative predictive values and and AUC equal to 0.90, 1, 0.8, 0.83, 1, and 0.99, respectively for the prediction of the presence of an elevated volume of non-calcified plaque from facial features among all 20 patients enrolled.
Conclusions
Prediction of the presence of high risk atherosclerosis from deep learning models applied to facial features appeared to be feasible and promising. Our results may provide a useful tool for appropriate identification of patients that may merit to underwent cardiac CT, even if asymptomatic, for early identification of high risk atherosclerosis
Funding Acknowledgement
Type of funding sources: None.
Collapse
Affiliation(s)
- E Conte
- IRCCS Monzino Cardiology Center , Milan , Italy
| | - M Chiesa
- IRCCS Monzino Cardiology Center , Milan , Italy
| | - S Mushtaq
- IRCCS Monzino Cardiology Center , Milan , Italy
| | - M Schillaci
- IRCCS Monzino Cardiology Center , Milan , Italy
| | - D Marchetti
- IRCCS Monzino Cardiology Center , Milan , Italy
| | - A Baggiano
- IRCCS Monzino Cardiology Center , Milan , Italy
| | - A Volpe
- IRCCS Monzino Cardiology Center , Milan , Italy
| | - G Colombo
- IRCCS Monzino Cardiology Center , Milan , Italy
| | - G Pompilio
- IRCCS Monzino Cardiology Center , Milan , Italy
| | | | - G Pontone
- IRCCS Monzino Cardiology Center , Milan , Italy
| | - D Andreini
- IRCCS Monzino Cardiology Center , Milan , Italy
| |
Collapse
|
4
|
Lippi M, Chiesa M, Ascione C, Pedrazzini M, Mushtaq S, Rovina D, Riggio D, Di Blasio A, Biondi ML, Pompilio G, Colombo GI, Novelli V, Casella M, Sommariva E. Spectrum of rare and common genetic variants in arrhythmogenic cardiomyopathy. Eur Heart J 2022. [DOI: 10.1093/eurheartj/ehac544.362] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Abstract
Background
Arrhythmogenic cardiomyopathy (ACM) is a rare inherited cardiac disorder, whose genetic cause is elusive in about 50% of cases. ACM pathogenic mutations mainly involve desmosomal genes (PKP2, JUP, DSP, DSG2, DSC2). ACM presents a variable disease course, spanning from mild electrocardiographic alterations and/or contractile dysfunctions, to malignant ventricular arrhythmias and heart failure.
Purpose
In an attempt to broaden etiological diagnosis for ACM patients, this work was aimed at finding potential rare high-impact variants in genes not previously associated with ACM. Secondarily, we meant to assess the impact of genetic polymorphisms on the disease clinical severity.
Methods
We clinically characterized 82 consecutive ACM probands and performed next-generation sequencing, exploring a panel of 174 genes associated with inherited cardiovascular diseases. We evaluated the pathogenicity of rare variants, according to the American College of Medical Genetics / Association for Molecular Pathology guidelines, to select candidates with potential ACM causative role. Further, a genotype-phenotype correlation analysis between common polymorphisms and clinical variables was performed to find genetic factors associated with specific ACM phenotypes. Finally, we carried out event-free survival analyses, linking specific variants to arrhythmias in 8,6±0,7 years follow-up, to estimate their possible impact on arrhythmic risk.
Results
We identified 141 rare genetic variants, of which 23 were classified of high impact, including variants in genes never associated with ACM (e.g. ABCC9, APOB, MIB1). These genes deserve future studies as they could participate in ACM pathogenesis. In addition, we found 69 genotype-phenotype significant associations (p≤0.005) between common variants and clinical parameters. Variants associated to arrhythmic phenotypes were found with genes linked to arrhythmias (e.g. KCNQ1, HCN4) and other cardiomyopathies (e.g. MYBPC3, MYL2). Associations involving substrate impairments were found with genes linked to muscle dysfunctions (e.g. LAMA2, SGCD). Arrhythmia-associated polymorphisms, included in survival analyses, were found to be associated with an increased occurrence of arrhythmic events during patients' follow-up.
Conclusion
The identification of rare high impact variants in novel genes potentially associated with ACM and the observation of genotype-phenotype correlations constitute the starting point to address the current lack of knowledge of the genetic landscape of ACM.
Funding Acknowledgement
Type of funding sources: Public grant(s) – National budget only. Main funding source(s): Ministero Italiano della Salute - Ricerca corrente
Collapse
Affiliation(s)
- M Lippi
- IRCCS Monzino Cardiology Center , Milan , Italy
| | - M Chiesa
- IRCCS Monzino Cardiology Center , Milan , Italy
| | - C Ascione
- IRCCS Monzino Cardiology Center , Milan , Italy
| | - M Pedrazzini
- Italian Auxological Institute San Luca Hospital , Milan , Italy
| | - S Mushtaq
- IRCCS Monzino Cardiology Center , Milan , Italy
| | - D Rovina
- IRCCS Monzino Cardiology Center , Milan , Italy
| | - D Riggio
- ASST Saints Paul and Charles , Milan , Italy
| | - A Di Blasio
- Italian Auxological Institute San Luca Hospital , Milan , Italy
| | - M L Biondi
- IRCCS Monzino Cardiology Center , Milan , Italy
| | - G Pompilio
- IRCCS Monzino Cardiology Center , Milan , Italy
| | - G I Colombo
- IRCCS Monzino Cardiology Center , Milan , Italy
| | - V Novelli
- IRCCS Monzino Cardiology Center , Milan , Italy
| | - M Casella
- University Hospital Riuniti of Ancona , Ancona , Italy
| | - E Sommariva
- IRCCS Monzino Cardiology Center , Milan , Italy
| |
Collapse
|
5
|
Penso M, Babbaro M, Guglielmo M, Moccia S, Giacari GM, Chiesa M, Maragna R, Rabbat MG, Pepi M, Pontone G. Artificial intelligence with spatial-attention for ventricular volumes and mass assessment in cardiac magnetic resonance images with susceptibility artifacts. Eur Heart J Cardiovasc Imaging 2022. [DOI: 10.1093/ehjci/jeac141.008] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Funding Acknowledgements
Type of funding sources: None.
Introduction
Segmentation of cardiac magnetic resonance (CMR) images is an essential step for evaluating dimensional and functional ventricular parameters but may limited by noise artefacts, such as the increasing diffusion of implantable devices causing distortion of the magnetic field.
Purpose
The aim of this paper is to investigate the accuracy of a deep learning (DL) approach for automatic segmentation of cardiac structures from CMR images characterized by magnetic susceptibility artifact images.
Methods
A retrospective database of SAX (short axis) cine CMR images obtained from 216 patients using a 1.5 Tesla scanner was used to develop and validate the proposed DL approach, subdividing patients into two subgroups, considering the presence (n=86) or absence (n=130) of a cardiac implantable electronic device. A novel convolutional neural network (CNN) was proposed to extract the left (LV) and right (RV) ventricle endocardium and left ventricle epicardium (LV mass). The proposed network takes advantage from a spatial attention module which introduces an adaptive feature refinement through a spatial weighting strategy to identify salient image regions even in the presence of artifacts. To improve segmentation, especially for images with artifacts, a compounded loss function is introduced. Segmentation results were assessed against manual tracings and commercial CMR analysis software.
Results
Results of correlation and Bland-Altman analyses on images with artifacts were reported for the proposed CNN and the commercial software (CS) in respect to the manual gold standard (GT). Also interobserver variability between O1 and O2 was tested. The proposed method reached higher segmentation accuracy than CS, with performance comparable to expert inter-observer variability (Picture 1). It is possible to appreciate how all the contours were properly depicted using the proposed CNN, with results comparable to the manual tracings. On the opposite, the CS resulted in imprecise segmentations of LV and RV endocardium and LV epicardium in presence of susceptibility artefacts caused by cardiac implantable electronic device affecting images' quality (Picture 2). Furthermore, the automatic approach was at least 100 times faster than manual segmentation in providing cardiac parameters.
Conclusion
The proposed method reached promising performance in cardiac segmentation from CMR images with susceptibility artifacts and alleviates time consuming expert physician contourn segmentation.
Collapse
Affiliation(s)
- M Penso
- Monzino Cardiology Centre , Milan , Italy
| | - M Babbaro
- IRCCS San Donato Polyclinic, Department of Clinical and Interventional Cardiology , San Donato Milanese , Italy
| | | | - S Moccia
- Sant'Anna School of Advanced Studies, The BioRobotics Institute and Department of Excellence in Robotics and AI , Pisa , Italy
| | | | - M Chiesa
- Monzino Cardiology Centre , Milan , Italy
| | - R Maragna
- Monzino Cardiology Centre , Milan , Italy
| | - M G Rabbat
- Loyola University , Chicago , United States of America
| | - M Pepi
- Monzino Cardiology Centre , Milan , Italy
| | - G Pontone
- Monzino Cardiology Centre , Milan , Italy
| |
Collapse
|
6
|
Myasoedova V, Massaiu I, Moschetta D, Chiesa M, Valerio V, Bozzi M, Parisi V, Poggio P. Sex-specific cell types and molecular pathways drive fibro-calcific aortic valve stenosis. Cardiovasc Res 2022. [DOI: 10.1093/cvr/cvac066.141] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Funding Acknowledgements
Type of funding sources: Foundation. Main funding source(s): Fondazione Gigi e Pupa Ferrari ONLUS
Background
Aortic stenosis (AS) is the most common valve disorder characterized by fibro-calcific remodeling of valve leaflets. Recent evidence indicated that there is a sex-related difference in AS development and progression. Fibrotic remodeling is peculiar of women's aortic valve, while men's aortic leaflets are more calcified than in women.
Purpose
To assess aortic valve fibrosis (AVF) in a severe AS cohort using non-invasive diagnostic tools and determine whether sex-specific pathological pathways and cell types are associated with severe AS.
Methods
We have included 28 men and 28 women matched for age with severe AS who underwent Doppler echocardiography and cardiac contrast-enhanced computed tomography (CT) before intervention. The calcium and fibrosis volumes were assessed and quantified using the ImageJ thresholding method, indexed calcium and fibrosis volume were calculated by dividing the volume by the aortic annular area. Differentially expressed genes and functional inferences between women and men's aortic valves were carried out on a publicly available microarray-based gene expression dataset (GSE102249). Cell types enrichment analysis in stenotic aortic valve tissues was used to reconstruct the sex-specific cellular composition of stenotic aortic valves.
Results
We confirmed that women had significantly lower aortic valve calcium content compared to men, while fibrotic tissue composition was significantly higher in women than men. We identified that the expression profile of human stenotic aortic valves is sex-dependent. Pro-fibrotic processes were prevalent in women, while pro-inflammatory ones, linked to the immune response system, were enhanced in men. Cell-type enrichment analysis showed that mesenchymal cells were over-represented in AS valves of women, whereas signatures for monocytes, macrophages, T and B cells were enriched men ones.
Conclusions
Our data provide the basis that the fibro-calcific process of the aortic valve is sex-specific, both at gene expression and cell type level. The quantification of aortic valve fibrosis by CT could make it possible to perform population-based studies and non-invasive assessment of novel therapies to reduce or halt sex-related calcific aortic valve stenosis (CAVS) progression, acting in an optimal window of opportunity early in the course of the disease.
Collapse
Affiliation(s)
| | - I Massaiu
- Cardiology Center Monzino IRCCS , Milan , Italy
| | - D Moschetta
- Cardiology Center Monzino IRCCS , Milan , Italy
| | - M Chiesa
- Cardiology Center Monzino IRCCS , Milan , Italy
| | - V Valerio
- Cardiology Center Monzino IRCCS , Milan , Italy
| | - M Bozzi
- Cardiology Center Monzino IRCCS , Milan , Italy
| | - V Parisi
- Federico II University Hospital, Dipartimento di Scienze Mediche Traslazionali , Naples , Italy
| | - P Poggio
- Cardiology Center Monzino IRCCS , Milan , Italy
| |
Collapse
|
7
|
Ocaña A, Chacón JI, Calvo L, Antón A, Mansutti M, Albanell J, Martínez MT, Lahuerta A, Bisagni G, Bermejo B, Semiglazov V, Thill M, Chan A, Morales S, Herranz J, Tusquets I, Chiesa M, Caballero R, Valagussa P, Bianchini G, Alba E, Gianni L. Derived Neutrophil-to-Lymphocyte Ratio Predicts Pathological Complete Response to Neoadjuvant Chemotherapy in Breast Cancer. Front Oncol 2022; 11:827625. [PMID: 35223459 PMCID: PMC8875201 DOI: 10.3389/fonc.2021.827625] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/02/2021] [Accepted: 12/24/2021] [Indexed: 12/28/2022] Open
Abstract
Background Derived neutrophil-to-lymphocyte ratio (dNLR) is a biomarker associated with clinical outcome in breast cancer (BC). We analyzed the association of dNLR with pathological complete response (pCR) in triple-negative BC (TNBC) patients receiving neoadjuvant chemotherapy (CT). Methods This is a retrospective analysis of two randomized studies involving early stage/locally advanced TNBC patients receiving anthracycline/taxane-based CT+/−carboplatin (GEICAM/2006-03) or nab-paclitaxel/paclitaxel followed by anthracycline regimen (ETNA). dNLR was calculated as the ratio of neutrophils to the difference between total leukocytes and neutrophils in peripheral blood before CT (baseline) and at the end of treatment (EOT). Logistic regression analyses were used to explore dNLR association with pCR. Results In total, 308 TNBC patients were analyzed, 216 from ETNA and 92 from GEICAM/2006-03. Baseline median dNLR was 1.61 (interquartile range (IQR): 1.25–2.04) and at EOT 1.53 (IQR: 0.96–2.22). Baseline dNLR showed positive correlation with increased tumor size (p-value = 1e−04). High baseline dNLR, as continuous variable or using median cutoff, was associated with lower likelihood of pCR in univariate analysis. High EOT dNLR as continuous variable or using quartiles was also associated with lower pCR rate in uni- and multivariate analyses. Conclusions High baseline and EOT dNLR correlates with lower benefit from neoadjuvant CT in TNBC.
Collapse
Affiliation(s)
- Alberto Ocaña
- Hospital Clínico San Carlos, Madrid e Instituto de Investigación Sanitaria San Carlos (IdISSC), Madrid and Universidad de Castilla La Mancha, Albacete, Spain.,Centro de Investigación Biomédica en Red de Oncología, CIBERONC-ISCIII, Madrid, Spain.,GEICAM Spanish Breast Cancer Group, San Sebastián de los Reyes, Madrid, Spain
| | - Jose Ignacio Chacón
- GEICAM Spanish Breast Cancer Group, San Sebastián de los Reyes, Madrid, Spain.,Oncology Department, Hospital Virgen de la Salud, Toledo, Spain
| | - Lourdes Calvo
- GEICAM Spanish Breast Cancer Group, San Sebastián de los Reyes, Madrid, Spain.,Oncology Department, Complejo Hospitalario Universitario de A Coruňa, A Coruňa, Spain
| | - Antonio Antón
- GEICAM Spanish Breast Cancer Group, San Sebastián de los Reyes, Madrid, Spain.,Hospital Universitario Miguel Servet, Instituto de Investigación Sanitaria de Aragón (IISA), Zaragoza, Spain
| | | | - Joan Albanell
- Centro de Investigación Biomédica en Red de Oncología, CIBERONC-ISCIII, Madrid, Spain.,GEICAM Spanish Breast Cancer Group, San Sebastián de los Reyes, Madrid, Spain.,Cancer Research Program, Hospital del Mar Medical Research Institute (IMIM), Oncology Department, Hospital del Mar, Barcelona, Spain.,Universitat Pompeu Fabra, Barcelona, Spain
| | - María Teresa Martínez
- Centro de Investigación Biomédica en Red de Oncología, CIBERONC-ISCIII, Madrid, Spain.,GEICAM Spanish Breast Cancer Group, San Sebastián de los Reyes, Madrid, Spain.,Hospital Clínico Universitario de Valencia, Biomedical Research Institute INCLIVA, Valencia, Spain
| | - Ainhara Lahuerta
- GEICAM Spanish Breast Cancer Group, San Sebastián de los Reyes, Madrid, Spain.,Oncology Department, Onkologikoa, San Sebastián, Spain
| | - Giancarlo Bisagni
- Oncology Department, Azienda USL-IRCCS di Reggio Emilia, Reggio Emilia, Italy
| | - Begoña Bermejo
- Centro de Investigación Biomédica en Red de Oncología, CIBERONC-ISCIII, Madrid, Spain.,GEICAM Spanish Breast Cancer Group, San Sebastián de los Reyes, Madrid, Spain.,Hospital Clínico Universitario de Valencia, Biomedical Research Institute INCLIVA, Valencia, Spain
| | - Vladimir Semiglazov
- Oncology Department, NN Petrov Research Inst of Oncology, St. Petersburg, Russia
| | - Marc Thill
- Oncology Department, Agaplesion Markus Krankenhaus, Frankfurt am Main, Germany
| | - Arlene Chan
- Breast Cancer Research Center, Curtin University, Perth, WA, Australia
| | - Serafin Morales
- GEICAM Spanish Breast Cancer Group, San Sebastián de los Reyes, Madrid, Spain.,Oncology Department, Hospital Universitario Arnau de Vilanova de Lleida, Lleida, Spain
| | - Jesús Herranz
- GEICAM Spanish Breast Cancer Group, San Sebastián de los Reyes, Madrid, Spain
| | - Ignacio Tusquets
- Centro de Investigación Biomédica en Red de Oncología, CIBERONC-ISCIII, Madrid, Spain.,GEICAM Spanish Breast Cancer Group, San Sebastián de los Reyes, Madrid, Spain.,Universitat Pompeu Fabra, Barcelona, Spain
| | - Massimo Chiesa
- GEICAM Spanish Breast Cancer Group, San Sebastián de los Reyes, Madrid, Spain
| | - Rosalía Caballero
- GEICAM Spanish Breast Cancer Group, San Sebastián de los Reyes, Madrid, Spain
| | | | | | - Emilio Alba
- Centro de Investigación Biomédica en Red de Oncología, CIBERONC-ISCIII, Madrid, Spain.,GEICAM Spanish Breast Cancer Group, San Sebastián de los Reyes, Madrid, Spain.,Hospitales Universitarios Regional y Virgen de la Victoria, IBIMA, Malaga, Spain
| | | |
Collapse
|
8
|
Myasoedova V, Fraschini E, Mostardini G, Bonfanti L, Chiesa M, De Pasquale C, Olivares P, Trabattoni D, Bartorelli AL, Andreini D, Poggio P. Sex difference in aortic valve fibrosis assessed by contrast-enhanced computed tomography in severe aortic stenosis. Eur Heart J 2021. [DOI: 10.1093/eurheartj/ehab724.1618] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Background
Aortic stenosis (AS) is characterized by fibro-calcific remodeling of aortic valve leaflets. Progressive aortic valve calcification (AVC) occurs in both sexes and cardiac computed tomography (CT) is recognized as a high-quality technique for AVC evaluation. To date, sex-specific CT thresholds of AVC have been implemented in clinical practice since it is now recognized that women have less AVC burden than men. In addition, recent evidences indicate that women have more fibrotic remodeling of aortic valve leaflet compared to men.
Purpose
Aortic valve fibrosis (AVF) being a significant contributor to valve gradient, we sought to evaluate the difference in AVF burden between men and women with severe AS using contrast-enhanced CT.
Methods
We included 56 patients matched for age and sex with severe AS. All patients underwent Doppler echocardiography and cardiac CT before intervention. Contrast attenuation values (Hounsfield Units, HU) and contrast-to-noise ratio were measured at the level of the ascending aorta. Total AVF was assessed based on HU ranging between 30 and 350, adjusting the upper threshold by increments of 25 HU in either direction until blood pool was not highlighted. Indexed contrast-enhanced CT calcium volume (iAVC) and fibrosis volume (iAVF) were calculated dividing the volumes by the aortic annular area. Fibro-calcific ratio was calculate dividing iAVF by iAVC volumes.
Results
There was no difference between men and women in major cardiovascular risk factors, valve phenotype (bicuspid vs. tricuspid), nor pharmacological treatment. Men had higher body surface area than women (1.89±0.14 vs. 1.67±0.17 m2, respectively; p<0.001), while women had lower aortic valve area than men (AVA; 0.74±0.2 vs. 0.91±0.2 cm2, respectively; p=0.007) but similar indexed AVA (0.44±0.15 vs. 0.48±0.12 cm2/m2, respectively; p=0.262). Women had significantly lower iAVC compared to men (36 [36–72] vs. 72 [67–123] mm3/cm2, respectively; p=0.03). However, iAVF was significantly higher in women compared to men (83 [78–123] vs. 63 [58–83] mm3/cm2, respectively; p=0.006). Finally, the fibro-calcific ratio, which indicates the predominance of valve fibrosis if >1.0, was significantly higher in women compared to men (2.57 [2.14–7.02] vs. 0.78 [0.84–2.02], respectively; p=0.003).
Conclusions
Our study highlights for the first time a sex difference in the fibrotic content of severe AS evaluated by contrast-enhanced CT. These findings might be valuable to promote further studies on the role of sex-specific tissue composition in AS progression and outcomes.
Funding Acknowledgement
Type of funding sources: Foundation. Main funding source(s): Fondazione Gigi e Pupa Ferrari ONLUS
Collapse
Affiliation(s)
| | - E Fraschini
- Cardiology Center Monzino IRCCS, Milan, Italy
| | | | - L Bonfanti
- Cardiology Center Monzino IRCCS, Milan, Italy
| | - M Chiesa
- Cardiology Center Monzino IRCCS, Milan, Italy
| | | | - P Olivares
- Cardiology Center Monzino IRCCS, Milan, Italy
| | | | | | - D Andreini
- Cardiology Center Monzino IRCCS, Milan, Italy
| | - P Poggio
- Cardiology Center Monzino IRCCS, Milan, Italy
| |
Collapse
|
9
|
Chiesa A, Chizzini M, Garlatti E, Salvadori E, Tacchino F, Santini P, Tavernelli I, Bittl R, Chiesa M, Sessoli R, Carretta S. Assessing the Nature of Chiral-Induced Spin Selectivity by Magnetic Resonance. J Phys Chem Lett 2021; 12:6341-6347. [PMID: 34228926 PMCID: PMC8397348 DOI: 10.1021/acs.jpclett.1c01447] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/05/2021] [Accepted: 06/21/2021] [Indexed: 05/20/2023]
Abstract
Understanding chiral-induced spin selectivity (CISS), resulting from charge transport through helical systems, has recently inspired many experimental and theoretical efforts but is still the object of intense debate. In order to assess the nature of CISS, we propose to focus on electron-transfer processes occurring at the single-molecule level. We design simple magnetic resonance experiments, exploiting a qubit as a highly sensitive and coherent magnetic sensor, to provide clear signatures of the acceptor polarization. Moreover, we show that information could even be obtained from time-resolved electron paramagnetic resonance experiments on a randomly oriented solution of molecules. The proposed experiments will unveil the role of chiral linkers in electron transfer and could also be exploited for quantum computing applications.
Collapse
Affiliation(s)
- A. Chiesa
- Dipartimento
di Scienze Matematiche, Fisiche e Informatiche, Università di Parma, I-43124 Parma, Italy
- UdR
Parma, INSTM, I-43124 Parma, Italy
| | - M. Chizzini
- Dipartimento
di Scienze Matematiche, Fisiche e Informatiche, Università di Parma, I-43124 Parma, Italy
| | - E. Garlatti
- Dipartimento
di Scienze Matematiche, Fisiche e Informatiche, Università di Parma, I-43124 Parma, Italy
- UdR
Parma, INSTM, I-43124 Parma, Italy
| | - E. Salvadori
- Dipartimento
di Chimica & NIS Centre, Università
di Torino, Via P. Giuria
7, I-10125 Torino, Italy
| | - F. Tacchino
- IBM
Quantum, IBM Research—Zurich, Säumerstrasse 4, 8803 Rüschlikon, Switzerland
| | - P. Santini
- Dipartimento
di Scienze Matematiche, Fisiche e Informatiche, Università di Parma, I-43124 Parma, Italy
- UdR
Parma, INSTM, I-43124 Parma, Italy
| | - I. Tavernelli
- IBM
Quantum, IBM Research—Zurich, Säumerstrasse 4, 8803 Rüschlikon, Switzerland
| | - R. Bittl
- Freie
Universität Berlin, Fachbereich Physik, Berlin Joint EPR Lab, Arnimallee 14, D-14195 Berlin, Germany
| | - M. Chiesa
- Dipartimento
di Chimica & NIS Centre, Università
di Torino, Via P. Giuria
7, I-10125 Torino, Italy
| | - R. Sessoli
- Dipartimento
di Chimica “Ugo Schiff” & INSTM, Università Degli Studi di Firenze, I-50019 Sesto Fiorentino, Italy
| | - S. Carretta
- Dipartimento
di Scienze Matematiche, Fisiche e Informatiche, Università di Parma, I-43124 Parma, Italy
- UdR
Parma, INSTM, I-43124 Parma, Italy
| |
Collapse
|
10
|
Palazón-Carrión N, Jiménez-Cortegana C, Sánchez-León ML, Henao-Carrasco F, Nogales-Fernández E, Chiesa M, Caballero R, Rojo F, Nieto-García MA, Sánchez-Margalet V, de la Cruz-Merino L. Circulating immune biomarkers in peripheral blood correlate with clinical outcomes in advanced breast cancer. Sci Rep 2021; 11:14426. [PMID: 34257359 PMCID: PMC8277895 DOI: 10.1038/s41598-021-93838-w] [Citation(s) in RCA: 17] [Impact Index Per Article: 5.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/09/2021] [Accepted: 06/30/2021] [Indexed: 11/09/2022] Open
Abstract
Identification of the different elements intervening at the tumor microenvironment seems key to explain clinical evolution in several tumor types. In this study, a set of immune biomarkers (myeloid derived suppressor cells, regulatory T cells, and OX40 + and PD-1 + T lymphocytes counts) in peripheral blood of patients diagnosed with advanced breast cancer were analyzed along of first line antineoplastic therapy. Subsequently, a comparison between groups with clinical benefit versus progression of disease and with a healthy women cohort was executed. Results reflected that patients showed higher basal levels of myeloid derived suppressor cells (35.43, IR = 180.73 vs 17.53, IR = 16.96 cells/μl; p = 0.001) and regulatory T cells (32.05, IR = 29.84 vs 22.61, IR = 13.57 cells/μl; p = 0.001) in comparison with healthy women. Furthermore, an increase in the number of activated T lymphocytes (expressing OX40), a decrease of immune inhibitory cells (MDSCs and Tregs) and inhibited T lymphocytes (expressing PD-1) were observed along the treatment in patients with clinical benefit (p ≤ 0.001). The opposite trend was observed in the case of disease progression. These findings suggest that some critical immune elements can be easily detected and measured in peripheral blood, which open a new opportunity for translational research, as they seem to be correlated with clinical evolution, at least in ABC.
Collapse
Affiliation(s)
| | - Carlos Jiménez-Cortegana
- Department of Medical Biochemistry and Molecular Biology, and Immunology, School of Medicine, Virgen Macarena University Hospital, University of Seville, Seville, Spain
| | - M Luisa Sánchez-León
- Clinical Oncology Department, Virgen Macarena University Hospital, Seville, Spain
| | | | | | - Massimo Chiesa
- GEICAM (Spanish Breast Cancer Research Group), Madrid, Spain
| | | | - Federico Rojo
- Pathology Department, IIS-Fundación Jimenez Diaz-CIBERONC, Madrid, Spain
| | | | - Víctor Sánchez-Margalet
- Department of Medical Biochemistry and Molecular Biology, and Immunology, School of Medicine, Virgen Macarena University Hospital, University of Seville, Seville, Spain.
| | - Luis de la Cruz-Merino
- Clinical Oncology Department, Virgen Macarena University Hospital, Seville, Spain.
- GEICAM (Spanish Breast Cancer Research Group), Madrid, Spain.
- Medicine Department, University of Seville, Seville, Spain.
| |
Collapse
|
11
|
Fontanella MM, Bacigaluppi S, Doglietto F, Zanin L, Agosti E, Panciani P, Belotti F, Saraceno G, Spena G, Draghi R, Fiorindi A, Cornali C, Biroli A, Kivelev J, Chiesa M, Retta SF, Gasparotti R, Kato Y, Hernesniemi J, Rigamonti D. An international call for a new grading system for cerebral and cerebellar cavernomas. J Neurosurg Sci 2021; 65:239-246. [PMID: 34184861 DOI: 10.23736/s0390-5616.21.05433-3] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
Surgical indications for cerebral cavernous malformations remain significantly center- and surgeon-dependent. Available grading systems are potentially limited, as they do not include epileptological and radiological data. A novel grading system is proposed for supratentorial and cerebellar cavernomas: it considers neuroradiological features (bleeding, increase in size), neurological status (focal deficits and seizures), location of the lesion and age of the patient. The score ranges from -1 to 10; furthermore, surgery should be considered when a score of 4 or higher is present. Based on neuroradiological characteristics, 0 points are assigned if the CCM is stable in size at different neuroradiological controls, 1 point if there is an increase in volume during follow-up, 2 points if intra- or extra-lesional bleeding <1 cm is present and 3 points if the CCM produced a hematoma >1 cm. Regarding focal neurological deficits, 0 points are assigned if absent and 2 points if present. For seizures, 0 points are assigned if absent, 1 point if present, but controlled by medications, and 2 points if drug resistant. We considered the site of the CCM, and in case of deep-seated lesions in a critical area (basal ganglia, thalamus) 1 point (-1) is subtracted, while for subcortical or deep cerebellar lesions 0 points are assigned, for CCMs in a cortical critical area 1 point is assigned and in case of lesions in cortical not in critical area or superficial cerebellar area, 2 points are assigned. As far as age is concerned, 0 points are assigned for patients older than 50 years and 1 point for patients younger than 50. In conclusion, a novel grading for surgical decision making in cerebral cavernomas, based on the experience of selected neurosurgeons, basic scientists, and patients, is suggested with the aim of further improving and standardizing the treatment of CCMs. The aim of this paper was also to call for both retrospective and prospective multicenter studies with the aim of testing the efficacy of the grading system in different centers.
Collapse
Affiliation(s)
- Marco M Fontanella
- Unit of Neurosurgery, Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, University of Brescia, Brescia, Italy
| | | | - Francesco Doglietto
- Unit of Neurosurgery, Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, University of Brescia, Brescia, Italy
| | - Luca Zanin
- Unit of Neurosurgery, Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, University of Brescia, Brescia, Italy -
| | - Edoardo Agosti
- Unit of Neurosurgery, Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, University of Brescia, Brescia, Italy
| | - Pierpaolo Panciani
- Unit of Neurosurgery, Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, University of Brescia, Brescia, Italy
| | - Francesco Belotti
- Unit of Neurosurgery, Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, University of Brescia, Brescia, Italy
| | - Giorgio Saraceno
- Unit of Neurosurgery, Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, University of Brescia, Brescia, Italy
| | | | - Riccardo Draghi
- Department of Neurosurgery, Maria Cecilia Hospital, GVM Care & Research, Cotignola, Ravenna, Italy
| | - Alessandro Fiorindi
- Unit of Neurosurgery, Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, University of Brescia, Brescia, Italy
| | - Claudio Cornali
- Unit of Neurosurgery, Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, University of Brescia, Brescia, Italy
| | - Antonio Biroli
- Unit of Neurosurgery, Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, University of Brescia, Brescia, Italy
| | - Juri Kivelev
- Department of Neurosurgery, Neurocenter, Turku University Hospital, Turku, Finland
| | | | - Saverio F Retta
- Department of Clinical and Biological Sciences, University of Turin, Turin, Italy.,CCM Italian Research Network, National Coordination Center at the Department of Clinical and Biological Sciences, University of Turin, Turin, Italy
| | - Roberto Gasparotti
- Unit of Neuroradiology, Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, University of Brescia, Brescia, Italy
| | - Yoko Kato
- Department of Neurosurgery, Fujita Health University Aichi, Toyoake, Japan
| | | | | |
Collapse
|
12
|
De la Cruz L, Gion M, Cruz J, Alonso JL, Quiroga V, Moreno F, Santisteban M, Andrés R, Holgado E, Palazón N, Rodríguez LM, Soto A, Cortés J, Cortés A, Ramos M, Casas M, Chiesa M, Bezares S, Caballero R, Rojo F. Abstract PS4-38: Association of tumor infiltrating lymphocytes (TILs) density and PD-L1 expression with pembrolizumab (P) plus gemcitabine (Gem) efficacy in patients with HER2-negative advanced breast cancer (ABC) from the GEICAM/2015-04 (PANGEA-Breast) study. Cancer Res 2021. [DOI: 10.1158/1538-7445.sabcs20-ps4-38] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background Immune cells (ICs) infiltration and immune checkpoints have been shown to be important for BC patients’ (pts) prognosis and response to immunotherapy. We aimed to analyze the relation between TILs prevalence and PD-L1 expression with efficacy to an immunostimulatory combination with P and Gem in ABC HER2-negative pts previously treated with ≤4 chemotherapy and/or ≥2 hormone therapy lines from the PANGEA-Breast trial (NCT03025880). Methods Pre-treatment (ttm) metastatic BC samples were assessed for TILs density [% of occupied stromal area upon H&E staining] and for PD-L1 immunohistochemistry expression using monoclonal anti-PD-L1 antibody clone 22C3 (Merck) by calculating ICs score (% of positive infiltrated ICs) and combined positive score [CPS; PD-L1 stained cells (tumor cells, lymphocytes, macrophages) divided by total viable tumor cells, multiplied by 100]. Cut-offs ≥5%, ≥10%, ≥30% were explored for TILs. PD-L1 scores were considered positive if ≥1%. Cut-offs (≥5%, ≥20%, ≥50%) were additionally assessed for PD-L1 as CPS. Logistic regression models were used to evaluate association between TILs density and PD-L1 expression with ttm efficacy in terms of Objective Response Rate [ORR; Complete + Partial Response (CR + PR)], Clinical Benefit Rate [CBR; CR + PR + Stable Disease ≥24 weeks] and Progression Free Survival (PFS), according to RECIST v1.1. Results Thirty-six pts were included, 58% had triple negative BC and 98% ECOG score ≤1. Median number of prior ttm lines was 4. ORR and CBR were 15.2% and 17%, respectively; median PFS was 3.1 months. TILs and PD-L1 were evaluated in 30 and 29 pts, respectively. No association was found between TILs density and ttm efficacy in terms of ORR, CBR and PFS. Analysis of PD-L1 ICs score did not reveal any significant association with ORR, CBR or PFS. However, pts with negative PD-L1 expression by CPS (<1%) had a significantly prolonged PFS [p-value=0.031; HR 0.39 (95%CI 0.16; 0.95)], not maintained at CPS <20% cut-off [p-value=0.062; HR 0.42 (95%CI 0.17; 1.08)]. Conclusions Our findings support that: 1) P plus Gem ttm in heavily pre-treated HER2-negative ABC pts obtains a modest ORR of 15.2%; 2) TILs density and PD-L1 expression in ICs does not predict its benefit; 3) PD-L1 in tumor cells scored as CPS impacts in worse outcome (PFS) but not in ORR, suggesting an eventual prognostic role in this population; 4) no long-term responders were observed with P plus Gem in this trial.
Citation Format: Luis De la Cruz, María Gion, Josefina Cruz, Jose Luis Alonso, Vanesa Quiroga, Fernando Moreno, Marta Santisteban, Raquel Andrés, Esther Holgado, Natalia Palazón, Luz Milva Rodríguez, Asunción Soto, Javier Cortés, Alfonso Cortés, Manuel Ramos, Maribel Casas, Massimo Chiesa, Susana Bezares, Rosalía Caballero, Federico Rojo. Association of tumor infiltrating lymphocytes (TILs) density and PD-L1 expression with pembrolizumab (P) plus gemcitabine (Gem) efficacy in patients with HER2-negative advanced breast cancer (ABC) from the GEICAM/2015-04 (PANGEA-Breast) study [abstract]. In: Proceedings of the 2020 San Antonio Breast Cancer Virtual Symposium; 2020 Dec 8-11; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2021;81(4 Suppl):Abstract nr PS4-38.
Collapse
Affiliation(s)
- Luis De la Cruz
- 1Hospital Universitario Virgen de la Macarena. GEICAM Spanish Breast Cancer Group, Seville, Spain
| | - María Gion
- 2Hospital Universitario Ramón y Cajal; Fundación Jiménez Díaz; GEICAM Spanish Breast Cancer Group, Madrid, Spain
| | - Josefina Cruz
- 3Hospital Universitario de Canarias. GEICAM Spanish Breast Cancer Group., Santa Cruz de Tenerife, Spain
| | - Jose Luis Alonso
- 4Hospital Universitario Virgen de la Arrixaca-IMIB. GEICAM Spanish Breast Cancer Group, Murcia, Spain
| | - Vanesa Quiroga
- 5Badalona Applied Research Group in Oncology (B-ARGO Group), Catalan Institute of Oncology. GEICAM Spanish Breast Cancer Group, Badalona, Barcelona, Spain
| | - Fernando Moreno
- 6Hospital Clínico Universitario San Carlos. GEICAM Spanish Breast Cancer Group, Madrid, Spain
| | - Marta Santisteban
- 7Clínica Universidad de Navarra. GEICAM Spanish Breast Cancer Group, Navarra, Spain
| | - Raquel Andrés
- 8Hospital Clínico Universitario Lozano Blesa. GEICAM Spanish Breast Cancer Group, Zaragoza, Spain
| | - Esther Holgado
- 9IOB Institute of Oncology, Hospital Ruber Juan Bravo. GEICAM Spanish Breast Cancer Group, Madrid, Spain
| | - Natalia Palazón
- 1Hospital Universitario Virgen de la Macarena. GEICAM Spanish Breast Cancer Group, Seville, Spain
| | - Luz Milva Rodríguez
- 10Hospital Universitario de Canarias. GEICAM Spanish Breast Cancer Group, Santa Cruz de Tenerife, Spain
| | - Asunción Soto
- 11IMIB-Hospital Universitario Virgen de la Arrixaca. GEICAM Spanish Breast Cancer Group, Murcia, Spain
| | - Javier Cortés
- 12IOB Institute of Oncology, Quiron Group, Madrid & Barcelona/ES - Vall d´Hebron Institute of Oncology (VHIO).. GEICAM Spanish Breast Cancer Group, Madrid, Spain
| | | | - Manuel Ramos
- 14Centro Oncológico de Galicia. GEICAM Spanish Breast Cancer Group, A Coruña, Spain
| | | | | | | | | | - Federico Rojo
- 16Fundación Jimenez Díaz. GEICAM Spanish Breast Cancer Group, Madrid, Spain
| |
Collapse
|
13
|
Troiano G, Chiesa M, Ghisetti M, Gelpi A, Meggiorini A, Firmi AM, Clasadonte V. Management of Food and Feed Safety Alerts in ATS VAL PADANA (Italy). Eur J Public Health 2020. [DOI: 10.1093/eurpub/ckaa166.188] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Abstract
Issue
The rapid alert system is a procedure codified in the European Community, designed to guarantee the speed of communications and consequent measures, that should be adopted if a food or feed represents a serious risk for health.
Description of the Problem
ATS Val Padana implements several measures in cases of food or feed that don't satisfy safety requirements, imported, produced, processed, or distributed by companies located in its area of competence. ATS checks the completeness and effectiveness of the actions undertaken/planned by the food/feed industry operator. The checks are focused on: - Preparation of the distribution list Activation of withdrawal/recall procedures;information provided to consumers;management of the withdrawn products;adoption of measures to prevent the placement of product on the marketAdoption of the traceability systemNotification to the authorities
Results
In November 2018-November 2019, 205 alerts were registered (11 in 2018, 191 in 2019) and specifically: - Alert notifications (risk requiring rapid action in another country): 154 Information notifications for follow-up (product present or that could be placed on the market in another Member State): 22Information notifications for attention (product present only in the Notifier country or has not been placed on the market or is no longer on the market): 29
The notifications concerned: the Department of Veterinary and Safety of Animal Origin Food(89), the Department of Hygiene and Health Prevention (89), both departments jointly (27). ATS Val Padana has managed the alerts and closed them on average within 7.59 days (DS 5.80, range 0-42). In one case the alert was closed after a month.
Lessons
The effectiveness of the Alert System depends first of the communications speed, as well as of the guarantee of rapid times to analyze sampled matrices. Our results demonstrate how ATS Val Padana operates ensuring the maximum effectiveness of the Alert System.
Key messages
The rapid alert system is a codified procedure in the European Community, designed to guarantee the speed of communications and consequent measures. The effectiveness of the Alert System depends primarily on the speed of communications.
Collapse
|
14
|
Troiano G, Chiesa M, Cirrincione ML, Merisio J, Mondini F, Biazzi M, Mirelli M, Orsini O, Firmi AM, Clasadonte V. The Nutritional Surveillance at school: experiences from ATS Val Padana (Italy). Eur J Public Health 2020. [DOI: 10.1093/eurpub/ckaa166.190] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Background
Correct habits acquired in childhood positively affect the future health of the adult person. Therefore the school meal isn't as a simple satisfaction of nutritional needs, but also an important moment of health promotion, which involves teachers and parents.
Objectives
In ATS Val Padana the Food Hygiene and Nutrition Unit evaluates school menu at the beginning of each year (including special diets for specific diseases that require diet therapy). During the school year, trained personnel carries out inspections in schools, according to annual planning. During the inspection are evaluated: - Presence/respect of the validated school menu Number of mealsPeople preparing and administering mealsFood preparation and storageLiking by childrenManagement of special dietsManagement of the meal as an educational moment
Results
132 inspections were performed: 70 in 2018 and 62 in 2019. 23 (17.42%) were conducted in nursery schools, 62 (46.96%) in kindergartens, 44 (33.33%) in primary schools, 3 (2.27%) in middle schools. 47 (35.60%) were privately managed; 61 (46.21%) were also equipped with a kitchen for preparing meals. 41 inspections (31.06%) showed slight criticalities; 9 (6.81%) serious problems (poor hygiene, lack of control over special diets - which required further inspections). A statistically significant difference was observed (p = 0.02) between 2018 and 2019, with a clear decrease in criticality in 2019. No difference in the results of the checks was observed in relation to the type of school, management, and to the presence or not of a kitchen (all p > 0.05).
Conclusions
The effectiveness of the control system is represented by the relationship between non-conformities detected during the checks and the number of performed checks. In 2019, despite the controls have increased compared to the previous year, the incidence of non-conformities has decreased. This indicates that control activities is positive to improve the quality of the school meal.
Key messages
The school meal is a fundamental educational moment for children. Control activities have positive impact on the quality of the school meal.
Collapse
|
15
|
de la Haba J, Morales-Ruiz T, García-Alfonso P, Lorenzo JP, Calvo L, Antón A, Marquez R, Sánchez-Rovira P, Santaballa A, Ciruelos E, García-Ortiz MV, Roldán-Arjona T, Herranz J, Chiesa M, Caballero R, Gallego J, Rodríguez-Lescure Á. Abstract P4-10-28: Identification of a specific epigenetic signature in patients showing secondary hypertension upon anti-VEGF treatment from the GEICAM/2011-04 (BRECOL) study. Cancer Res 2020. [DOI: 10.1158/1538-7445.sabcs19-p4-10-28] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
BACKGROUND The appearance of secondary hypertension (HTN) is one of the most common side effects of anti-angiogenic agents since it emerges in over 50% of the patients with these therapies. Independently of tumor type, in most clinical trials it was possible to observe a positive association between secondary HTN and better clinical outcome, including Progression Free Survival (PFS) and Overall Survival (OS). Preeclampsia is one of the biological models that better resembles the anti-VEGF/VEGFR action of these therapies. DNA methylation is one of the epigenetic mechanisms potentially related to variation in susceptibility to gestational HTN. The objective of our study is to define a specific epigenetic signature that could predict secondary HTN to anti-angiogenic treatment in patients that received bevacizumab in combination with chemotherapy (CT) from the BRECOL study. METHODS Patients (n=113) from BRECOL study (NCT01733628) received bevacizumab in combination with oxaliplatin or irinotecan + fluoropyrimidines for metastatic colorectal cancer (n=49), and with paclitaxel or capecitabine for metastatic breast cancer (n=64). Blood pressure (BP) was recorded with a Holter measurement (24 hours registration starting 2 hours after treatment administration). A methylation analysis was carried out on DNA obtained from pretreatment peripheral blood samples in 32 patients (28%) distributed in 4 experimental groups (8 patients / each) and classified according to their HTN history and to their BP variation upon bevacizumab plus CT: • Group A: patients with HTN history and with BP increase • Group B: patients with HTN history and with no BP increase • Group C: patients without HTN history and with BP increase • Group D: patients without HTN history and with no BP increase Analysis was realized with the “Infinium Human Methylation EPIC BeadChip” array (Illumina®) on bisulfite-converted DNA and differentially methylated sites were identified with the LIMMA (“Linear Models for Microarray Analysis”) bioinformatics tool (Bioconductor®). RESULTS Upon analysis of 850000 different methylation sites distributed all over the genome, we identified 27 (18 localized in the coding regions of the genes: FMNL2, METTL3, ACOT6, SCARNA20, PREX1, DNAI2, RAET1G, KCNJ8, GDF7, SYNPO2, CUGBP1, FRMD8, MKL2, HIF1A, TMEM177, UTP23, PXK and TNPO1; 9 localized in intergenic regions) that are differentially methylated in patients that showed secondary HTN to bevacizumab plus CT, independently of HTN history (Groups A + C vs. B + D). Based on Principal Components (PC) analysis, we defined a methylation score predictive of elevated BP. First PC (PC1) explains the 83.2% of the variability of the 27 identified methylation sites and allows to distinguish between patients that do and do not show secondary HTN. CONCLUSIONS High BP upon anti-angiogenic treatment is associated to specific DNA methylation profiles. We identified an epigenetic methylation signature putative predictive of secondary HTN to bevacizumab treatment in metastatic breast and colorectal cancer.
Citation Format: Juan de la Haba, Teresa Morales-Ruiz, Pilar García-Alfonso, Jose Ponce Lorenzo, Lourdes Calvo, Antonio Antón, Raul Marquez, Pedro Sánchez-Rovira, Ana Santaballa, Eva Ciruelos, María Victoria García-Ortiz, Teresa Roldán-Arjona, Jesús Herranz, Massimo Chiesa, Rosalía Caballero, Javier Gallego, Álvaro Rodríguez-Lescure. Identification of a specific epigenetic signature in patients showing secondary hypertension upon anti-VEGF treatment from the GEICAM/2011-04 (BRECOL) study [abstract]. In: Proceedings of the 2019 San Antonio Breast Cancer Symposium; 2019 Dec 10-14; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2020;80(4 Suppl):Abstract nr P4-10-28.
Collapse
Affiliation(s)
- Juan de la Haba
- 1Instituto Maimónides de Investigación Biomédica de Córdoba. Hospital Reina Sofía. CIBERONC. GEICAM Spanish Breast Cancer Group, Córdoba, Spain
| | - Teresa Morales-Ruiz
- 2Instituto Maimónides de Investigación Biomédica de Córdoba. Hospital Reina Sofía, Córdoba, Spain
| | | | - Jose Ponce Lorenzo
- 4Hospital General de Alicante. GEICAM Spanish Breast Cancer Group, Alicante, Spain
| | - Lourdes Calvo
- 5Complejo Hospitalario Universitario A Coruña. GEICAM Spanish Breast Cancer Group, A Coruña, Spain
| | - Antonio Antón
- 6Hospital Universitario Miguel Servet. GEICAM Spanish Breast Cancer Group, Zaragoza, Spain
| | - Raul Marquez
- 7Centro Oncológico MD Anderson. GEICAM Spanish Breast Cancer Group, Madrid, Spain
| | | | - Ana Santaballa
- 9Hospital de la Fe de Valencia. GEICAM Spanish Breast Cancer Group, Valencia, Spain
| | - Eva Ciruelos
- 10Hospital Universitario 12 de Octubre. GEICAM Spanish Breast Cancer Group, Madrid, Spain
| | | | - Teresa Roldán-Arjona
- 2Instituto Maimónides de Investigación Biomédica de Córdoba. Hospital Reina Sofía, Córdoba, Spain
| | | | | | | | - Javier Gallego
- 6Hospital Universitario Miguel Servet. GEICAM Spanish Breast Cancer Group, Zaragoza, Spain
| | | |
Collapse
|
16
|
Ocaña A, Chacón JILM, Calvo L, Antón A, Mansutti M, Alba E, Lluch A, Lahuerta A, Bisagni G, Bermejo B, Semiglazov V, Thill M, Chan A, Morales S, Albanell J, Herranz J, Trias Bes IT, Valagussa P, Chiesa M, Gianni L. Association of derived neutrophil-to-lymphocyte ratio (dNLR) with pathological complete response (pCR) after neoadjuvant chemotherapy (CT). Ann Oncol 2019. [DOI: 10.1093/annonc/mdz240.094] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
17
|
Lozovaya N, Nardou R, Tyzio R, Chiesa M, Pons-Bennaceur A, Eftekhari S, Bui TT, Billon-Grand M, Rasero J, Bonifazi P, Guimond D, Gaiarsa JL, Ferrari DC, Ben-Ari Y. Early alterations in a mouse model of Rett syndrome: the GABA developmental shift is abolished at birth. Sci Rep 2019; 9:9276. [PMID: 31239460 PMCID: PMC6592949 DOI: 10.1038/s41598-019-45635-9] [Citation(s) in RCA: 40] [Impact Index Per Article: 8.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/14/2019] [Accepted: 06/11/2019] [Indexed: 02/06/2023] Open
Abstract
Genetic mutations of the Methyl-CpG-binding protein-2 (MECP2) gene underlie Rett syndrome (RTT). Developmental processes are often considered to be irrelevant in RTT pathogenesis but neuronal activity at birth has not been recorded. We report that the GABA developmental shift at birth is abolished in CA3 pyramidal neurons of Mecp2-/y mice and the glutamatergic/GABAergic postsynaptic currents (PSCs) ratio is increased. Two weeks later, GABA exerts strong excitatory actions, the glutamatergic/GABAergic PSCs ratio is enhanced, hyper-synchronized activity is present and metabotropic long-term depression (LTD) is impacted. One day before delivery, maternal administration of the NKCC1 chloride importer antagonist bumetanide restored these parameters but not respiratory or weight deficits, nor the onset of mortality. Results suggest that birth is a critical period in RTT with important alterations that can be attenuated by bumetanide raising the possibility of early treatment of the disorder.
Collapse
Affiliation(s)
- N Lozovaya
- Neurochlore, Ben-Ari Institute of Neuroarcheology (IBEN), Bâtiment Beret-Delaage, Parc scientifique et technologique de Luminy, 13288, Marseille, cedex 09, France
| | - R Nardou
- Neurochlore, Ben-Ari Institute of Neuroarcheology (IBEN), Bâtiment Beret-Delaage, Parc scientifique et technologique de Luminy, 13288, Marseille, cedex 09, France
| | - R Tyzio
- Neurochlore, Ben-Ari Institute of Neuroarcheology (IBEN), Bâtiment Beret-Delaage, Parc scientifique et technologique de Luminy, 13288, Marseille, cedex 09, France.,Mediterranean Institute of Neurobiology (INMED), Department of Neurobiology, Aix-Marseille University, INSERM U1249, 13273, Marseille, France
| | - M Chiesa
- Neurochlore, Ben-Ari Institute of Neuroarcheology (IBEN), Bâtiment Beret-Delaage, Parc scientifique et technologique de Luminy, 13288, Marseille, cedex 09, France.,Mediterranean Institute of Neurobiology (INMED), Department of Neurobiology, Aix-Marseille University, INSERM U1249, 13273, Marseille, France
| | - A Pons-Bennaceur
- Mediterranean Institute of Neurobiology (INMED), Department of Neurobiology, Aix-Marseille University, INSERM U1249, 13273, Marseille, France
| | - S Eftekhari
- Neurochlore, Ben-Ari Institute of Neuroarcheology (IBEN), Bâtiment Beret-Delaage, Parc scientifique et technologique de Luminy, 13288, Marseille, cedex 09, France.,Mediterranean Institute of Neurobiology (INMED), Department of Neurobiology, Aix-Marseille University, INSERM U1249, 13273, Marseille, France
| | - T-T Bui
- Neurochlore, Ben-Ari Institute of Neuroarcheology (IBEN), Bâtiment Beret-Delaage, Parc scientifique et technologique de Luminy, 13288, Marseille, cedex 09, France.,Mediterranean Institute of Neurobiology (INMED), Department of Neurobiology, Aix-Marseille University, INSERM U1249, 13273, Marseille, France
| | - M Billon-Grand
- Neurochlore, Ben-Ari Institute of Neuroarcheology (IBEN), Bâtiment Beret-Delaage, Parc scientifique et technologique de Luminy, 13288, Marseille, cedex 09, France
| | - J Rasero
- Biocruces Health Research Institute, 48903, Barakaldo, Spain
| | - P Bonifazi
- Biocruces Health Research Institute, 48903, Barakaldo, Spain.,IKERBASQUE: The Basque Foundation for Science, 48013, Bilbao, Spain
| | - D Guimond
- Neurochlore, Ben-Ari Institute of Neuroarcheology (IBEN), Bâtiment Beret-Delaage, Parc scientifique et technologique de Luminy, 13288, Marseille, cedex 09, France
| | - J-L Gaiarsa
- Mediterranean Institute of Neurobiology (INMED), Department of Neurobiology, Aix-Marseille University, INSERM U1249, 13273, Marseille, France
| | - D C Ferrari
- Neurochlore, Ben-Ari Institute of Neuroarcheology (IBEN), Bâtiment Beret-Delaage, Parc scientifique et technologique de Luminy, 13288, Marseille, cedex 09, France
| | - Y Ben-Ari
- Neurochlore, Ben-Ari Institute of Neuroarcheology (IBEN), Bâtiment Beret-Delaage, Parc scientifique et technologique de Luminy, 13288, Marseille, cedex 09, France.
| |
Collapse
|
18
|
Palazón-Carrión N, Jiménez-Cortegana C, Holgado E, Jurado JC, Alonso Romero JL, Sánchez Leon ML, Sanchez Margalet V, Nogales E, Moreno Anton F, Quiroga Garcia V, Andres R, Santisteban M, Cortes J, Rodríguez-Rodríguez LM, Soto Gutierrez A, Cortes MG, Nieto Garcia A, Chiesa M, Bezares S, De la Cruz-Merino L. Evolution of the myeloid-derived suppressor cells in advanced breast cancer and comparative analysis with a healthy population cohort. J Clin Oncol 2019. [DOI: 10.1200/jco.2019.37.15_suppl.2543] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
2543 Background: High levels of myeloid-derived suppressor cells (MDSCs) seem a negative prognostic factor in advanced breast cancer (ABC) patients (pts). Preclinical studies suggest an immunomodulatory effect of some classical anti-tumor agents through alteration of MDSCs homeostasis. We analyzed the association of MDSCs and clinical evolution of ABC pts, taking into account the systemic treatment (tx) modulation of MDSCs levels in pts from two studies (“A”: GEICAM/2015-04 PANGEA-BREAST, NCT03025880 “Efficacy and Safety of Pembrolizumab and Gemcitabine in HER2-negative ABC”, and “B”: PI-0502-2014 “Peripheral blood analyses of immune response induced by 1st line tx of ABC according to clinical guidelines”). Methods: MDSCs (CD33+ CD11b+) levels were determined by flow-cytometry in peripheral blood samples at three time points (basal, at cycles 3 and 6) from: 39 HER2-negative heavily pretreated pts from study “A”, 43 non-pretreated pts (all subtypes) from study “B” and 20 women from a healthy cohort (HC), with no cancer diagnosis. MDSCs levels from the different cohorts were compared and correlated with pts with Clinical Benefit (CB: partial/complete response + disease stabilization) vs pts with Progressive Disease (PD). Results: Tx response was assessed in 33 pts (85%) from study “A” and 39 pts (91%) from study “B”. CB was observed in 11 pts (28%) from study “A” and in 34 (79%) from study “B” while PD was observed in 22 pts (56%) from study “A” and in 5 (12%) from study “B”. Basal MDSCs levels were significantly higher in ABC pts (studies “A”+”B”) than in HC (15.95 vs 0.81 cells/µl, p = 0.009). At cycle 6, MDSCs were considerably lower in pts with CB vs DP (2.90 vs 13.75 cells/µl, p < 0.001). This decrease was more pronounced in study “B” than in study “A” pts (p < 0.001 vs p = 0.074, respectively), probably due to differences in number of events, tumor subtypes and tx between both studies. Conclusions: Our results suggest that ABC pts show alterations in MDSCs and that their decrease along tx may have a positive predictive value, highlighting the importance that immune-competent status may play in the evolution of ABC. MDSCs may represent a target for therapeutic purposes in ABC.
Collapse
Affiliation(s)
| | | | - Esther Holgado
- Hospital Universitario Ramón y Cajal, GEICAM Spanish Breast Cancer Group, Madrid, Spain
| | - Josefina Cruz Jurado
- Hospital Universitario de Canarias, GEICAM Spanish Breast Cancer Group, Santa Cruz de Tenerife, Spain
| | - Jose Luis Alonso Romero
- Hospital Clinico Universitario Virgen de la Arrixaca, GEICAM Spanish Breast Cancer Group, Murcia, Spain
| | | | | | | | - Fernando Moreno Anton
- Hospital Clínico Universitario San Carlos, Madrid, GEICAM, Spanish Breast Cancer Group, Madrid, Spain
| | - Vanesa Quiroga Garcia
- Badalona-Applied Research Group in Oncology: B-ARGO Group, Catalan Institute of Oncology, Spain-GEICAM, Spanish Breast Cancer Group, Barcelona, Spain
| | - Raquel Andres
- Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain, GEICAM Spanish Breast Cancer Group, Zaragoza, Spain
| | - Marta Santisteban
- Clínica Universidad de Navarra, Pamplona, GEICAM, Spanish Breast Cancer Group, Pamplona, Spain
| | - Javier Cortes
- IOB Institute of Oncology, Quironsalud Group, Madrid & Barcelona, Vall d´Hebron Institute of Oncology (VHIO), Barcelona, GEICAM, Spanish Breast Cancer Group, Madrid & Barcelona, Spain
| | | | - Asuncion Soto Gutierrez
- Hospital Universitario Virgen de la Arrixaca, GEICAM, Spanish Breast Cancer Group, Murcia, Spain
| | - Mana Gion Cortes
- Hospital Ramon y Cajal. GEICAM, Spanish Breast Cancer Group, Madrid, Spain
| | | | | | | | - Luis De la Cruz-Merino
- Hospital Universitario Virgen Macarena, GEICAM Spanish Breast Cancer Group, Seville, Spain
| |
Collapse
|
19
|
Alba E, Rueda OM, Lluch A, Albanell J, Chin SF, Chacón JI, Calvo L, De la Haba-Rodriguez J, Bermejo B, Ribelles N, Sánchez-Rovira P, Plazaola A, Barnadas A, Cirauqul B, Ramos M, Arcusa A, Carrasco E, Herranz J, Chiesa M, Caballero R, Santonja A, Rojo F, Caldas C. Abstract P5-12-03: Genome copy number entropy as predictor of response for neoadjuvant therapy in early breast cancer. Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-p5-12-03] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background
Copy Number Alterations (CNAs) represent changes in the copy number of genomic segments of somatic cells due to chromosomal instability. CNAs include gene amplifications or deletions and can be involved in tumorigenesis. We analyzed CNAs data in pre- and post-treatment (ttm) tumors from patients (pts) with early breast cancer (BC) in the neoadjuvant trials GEICAM/2006-03 and GEICAM/2006-14, with the aim to identify CNAs in particular genomic regions (genetic entropy) associated with treatment response.
Methods
GEICAM/2006-03 (NCT00432172) HER2-negative pts were selectively treated according to clinical subtypes: triple negative (TN) pts were treated with standard anthracycline/taxane -based chemotherapy (AT-CT) +/- carboplatin, while luminal patients were randomized to AT-CT vs. hormonotherapy; GEICAM/2006-14 (NCT00841828) HER2+ pts received AT-CT plus anti-HER2 therapy.Shallow-whole genome Illumina sequencing DNA data from 204 paraffin-embedded tumors (100 pre- and 104 post-ttm) were segmented to obtain CNAs and recurrent altered genomic regions were defined. We used Wilcoxon test to analyze the frequency of altered regions and logistic regression analyses to explore their association with tumor response, in terms of pathological complete response (pCR) in breast and axilla. Validation of altered genes associated with therapy response was performed in the microarray gene expression-based Hatzis dataset (GSE25066) from pts receiving neoadjuvant AT-CT (1).
Results
A total of 672 regions covering the whole genome were identified upon analysis of CNAs data. Regions were categorized according to their alteration status as amplified, normal and lost. Comparative analysis of alterations revealed 11 regions significantly different (p<0.05) in pre- vs post-ttm tumors. Logistic regression analysis showed that in pre-ttm tumors specific alterations of 8 regions localized in 3 different genomic loci (11q12, 16q22 and 21q22) were significantly associated with pCR (p<0.05). Independent analyses of CNAs data with “CGH regions” and “GISTIC2.0” tools confirmed the special relevance of 2 of these 8 regions (#653 and #654), amplified in the locus 21q22.12. This locus contains 20 genes whose expression was tested in Hatzis dataset (1) (GSE25066): the analysis showed that overexpression of 5 of these 20 genes (CHAF1B, CBR1, CBR3, RCAN1 and SLC5A3) turned out to be significantly higher in the cohort of pts who reached pCR, in agreement with our findings. Some of these genes have already been described as proliferation markers (CHAF1B) or involved in treatment response (CBR1) in BC. Other genes related to BC in this genomic region are the transcription factor RUNX1 and the Lysine Methyltransferase SETD4.
Conclusions
According to our results, neoadjuvant therapy can modulate genomic aberrations landscape in BC. Our data suggest that amplification of specific genes in the genomic locus (21q22.12) is involved in the neoadjuvant therapy response in early BC.
(1): Hatzis et al., JAMA 2011, 305(18) 1873-81
Citation Format: Alba E, Rueda OM, Lluch A, Albanell J, Chin S-F, Chacón JI, Calvo L, De la Haba-Rodriguez J, Bermejo B, Ribelles N, Sánchez-Rovira P, Plazaola A, Barnadas A, Cirauqul B, Ramos M, Arcusa A, Carrasco E, Herranz J, Chiesa M, Caballero R, Santonja A, Rojo F, Caldas C. Genome copy number entropy as predictor of response for neoadjuvant therapy in early breast cancer [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P5-12-03.
Collapse
Affiliation(s)
- E Alba
- Instituto de Investigación Biomédica de Málaga (IBIMA) - Hospital Clínico Universitario Virgen de la Victoria, Málaga, Spain; Centro de Investigación Biomédica en Red de Oncología, CIBERONC, Madrid, Spain; GEICAM, Spanish Breast Cancer Group, Madrid, Spain; Cancer Research UK Cambridge Institute, Li Ka Shing Centre, University of Cambridge, Cambridge, United Kingdom; Hospital Clínico Universitario de Valencia. Biomedical Research Institute INCLIVA. University of Valencia, Valencia, Spain; Hospital del Mar, Barcelona, Spain; Hospital Virgen de la Salud, Toledo, Spain; Complejo Hospitalario Universitario de A Coruña, A Coruña, Spain; Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC) - H. Universitario Reina Sofía, Universidad de Córdoba, Córdoba, Spain; Hospital Clínico Universitario de Valencia, Valencia, Spain; Complejo Hospitalario de Jaén, Jaen, Spain; Onkologikoa, San Sebastián, Spain; Hospital de la Santa Creu i Sant Pau, Barcelona, Spain; Hospital Germans Trias i Pujol, Barcelona, Spai
| | - OM Rueda
- Instituto de Investigación Biomédica de Málaga (IBIMA) - Hospital Clínico Universitario Virgen de la Victoria, Málaga, Spain; Centro de Investigación Biomédica en Red de Oncología, CIBERONC, Madrid, Spain; GEICAM, Spanish Breast Cancer Group, Madrid, Spain; Cancer Research UK Cambridge Institute, Li Ka Shing Centre, University of Cambridge, Cambridge, United Kingdom; Hospital Clínico Universitario de Valencia. Biomedical Research Institute INCLIVA. University of Valencia, Valencia, Spain; Hospital del Mar, Barcelona, Spain; Hospital Virgen de la Salud, Toledo, Spain; Complejo Hospitalario Universitario de A Coruña, A Coruña, Spain; Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC) - H. Universitario Reina Sofía, Universidad de Córdoba, Córdoba, Spain; Hospital Clínico Universitario de Valencia, Valencia, Spain; Complejo Hospitalario de Jaén, Jaen, Spain; Onkologikoa, San Sebastián, Spain; Hospital de la Santa Creu i Sant Pau, Barcelona, Spain; Hospital Germans Trias i Pujol, Barcelona, Spai
| | - A Lluch
- Instituto de Investigación Biomédica de Málaga (IBIMA) - Hospital Clínico Universitario Virgen de la Victoria, Málaga, Spain; Centro de Investigación Biomédica en Red de Oncología, CIBERONC, Madrid, Spain; GEICAM, Spanish Breast Cancer Group, Madrid, Spain; Cancer Research UK Cambridge Institute, Li Ka Shing Centre, University of Cambridge, Cambridge, United Kingdom; Hospital Clínico Universitario de Valencia. Biomedical Research Institute INCLIVA. University of Valencia, Valencia, Spain; Hospital del Mar, Barcelona, Spain; Hospital Virgen de la Salud, Toledo, Spain; Complejo Hospitalario Universitario de A Coruña, A Coruña, Spain; Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC) - H. Universitario Reina Sofía, Universidad de Córdoba, Córdoba, Spain; Hospital Clínico Universitario de Valencia, Valencia, Spain; Complejo Hospitalario de Jaén, Jaen, Spain; Onkologikoa, San Sebastián, Spain; Hospital de la Santa Creu i Sant Pau, Barcelona, Spain; Hospital Germans Trias i Pujol, Barcelona, Spai
| | - J Albanell
- Instituto de Investigación Biomédica de Málaga (IBIMA) - Hospital Clínico Universitario Virgen de la Victoria, Málaga, Spain; Centro de Investigación Biomédica en Red de Oncología, CIBERONC, Madrid, Spain; GEICAM, Spanish Breast Cancer Group, Madrid, Spain; Cancer Research UK Cambridge Institute, Li Ka Shing Centre, University of Cambridge, Cambridge, United Kingdom; Hospital Clínico Universitario de Valencia. Biomedical Research Institute INCLIVA. University of Valencia, Valencia, Spain; Hospital del Mar, Barcelona, Spain; Hospital Virgen de la Salud, Toledo, Spain; Complejo Hospitalario Universitario de A Coruña, A Coruña, Spain; Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC) - H. Universitario Reina Sofía, Universidad de Córdoba, Córdoba, Spain; Hospital Clínico Universitario de Valencia, Valencia, Spain; Complejo Hospitalario de Jaén, Jaen, Spain; Onkologikoa, San Sebastián, Spain; Hospital de la Santa Creu i Sant Pau, Barcelona, Spain; Hospital Germans Trias i Pujol, Barcelona, Spai
| | - S-F Chin
- Instituto de Investigación Biomédica de Málaga (IBIMA) - Hospital Clínico Universitario Virgen de la Victoria, Málaga, Spain; Centro de Investigación Biomédica en Red de Oncología, CIBERONC, Madrid, Spain; GEICAM, Spanish Breast Cancer Group, Madrid, Spain; Cancer Research UK Cambridge Institute, Li Ka Shing Centre, University of Cambridge, Cambridge, United Kingdom; Hospital Clínico Universitario de Valencia. Biomedical Research Institute INCLIVA. University of Valencia, Valencia, Spain; Hospital del Mar, Barcelona, Spain; Hospital Virgen de la Salud, Toledo, Spain; Complejo Hospitalario Universitario de A Coruña, A Coruña, Spain; Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC) - H. Universitario Reina Sofía, Universidad de Córdoba, Córdoba, Spain; Hospital Clínico Universitario de Valencia, Valencia, Spain; Complejo Hospitalario de Jaén, Jaen, Spain; Onkologikoa, San Sebastián, Spain; Hospital de la Santa Creu i Sant Pau, Barcelona, Spain; Hospital Germans Trias i Pujol, Barcelona, Spai
| | - JI Chacón
- Instituto de Investigación Biomédica de Málaga (IBIMA) - Hospital Clínico Universitario Virgen de la Victoria, Málaga, Spain; Centro de Investigación Biomédica en Red de Oncología, CIBERONC, Madrid, Spain; GEICAM, Spanish Breast Cancer Group, Madrid, Spain; Cancer Research UK Cambridge Institute, Li Ka Shing Centre, University of Cambridge, Cambridge, United Kingdom; Hospital Clínico Universitario de Valencia. Biomedical Research Institute INCLIVA. University of Valencia, Valencia, Spain; Hospital del Mar, Barcelona, Spain; Hospital Virgen de la Salud, Toledo, Spain; Complejo Hospitalario Universitario de A Coruña, A Coruña, Spain; Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC) - H. Universitario Reina Sofía, Universidad de Córdoba, Córdoba, Spain; Hospital Clínico Universitario de Valencia, Valencia, Spain; Complejo Hospitalario de Jaén, Jaen, Spain; Onkologikoa, San Sebastián, Spain; Hospital de la Santa Creu i Sant Pau, Barcelona, Spain; Hospital Germans Trias i Pujol, Barcelona, Spai
| | - L Calvo
- Instituto de Investigación Biomédica de Málaga (IBIMA) - Hospital Clínico Universitario Virgen de la Victoria, Málaga, Spain; Centro de Investigación Biomédica en Red de Oncología, CIBERONC, Madrid, Spain; GEICAM, Spanish Breast Cancer Group, Madrid, Spain; Cancer Research UK Cambridge Institute, Li Ka Shing Centre, University of Cambridge, Cambridge, United Kingdom; Hospital Clínico Universitario de Valencia. Biomedical Research Institute INCLIVA. University of Valencia, Valencia, Spain; Hospital del Mar, Barcelona, Spain; Hospital Virgen de la Salud, Toledo, Spain; Complejo Hospitalario Universitario de A Coruña, A Coruña, Spain; Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC) - H. Universitario Reina Sofía, Universidad de Córdoba, Córdoba, Spain; Hospital Clínico Universitario de Valencia, Valencia, Spain; Complejo Hospitalario de Jaén, Jaen, Spain; Onkologikoa, San Sebastián, Spain; Hospital de la Santa Creu i Sant Pau, Barcelona, Spain; Hospital Germans Trias i Pujol, Barcelona, Spai
| | - J De la Haba-Rodriguez
- Instituto de Investigación Biomédica de Málaga (IBIMA) - Hospital Clínico Universitario Virgen de la Victoria, Málaga, Spain; Centro de Investigación Biomédica en Red de Oncología, CIBERONC, Madrid, Spain; GEICAM, Spanish Breast Cancer Group, Madrid, Spain; Cancer Research UK Cambridge Institute, Li Ka Shing Centre, University of Cambridge, Cambridge, United Kingdom; Hospital Clínico Universitario de Valencia. Biomedical Research Institute INCLIVA. University of Valencia, Valencia, Spain; Hospital del Mar, Barcelona, Spain; Hospital Virgen de la Salud, Toledo, Spain; Complejo Hospitalario Universitario de A Coruña, A Coruña, Spain; Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC) - H. Universitario Reina Sofía, Universidad de Córdoba, Córdoba, Spain; Hospital Clínico Universitario de Valencia, Valencia, Spain; Complejo Hospitalario de Jaén, Jaen, Spain; Onkologikoa, San Sebastián, Spain; Hospital de la Santa Creu i Sant Pau, Barcelona, Spain; Hospital Germans Trias i Pujol, Barcelona, Spai
| | - B Bermejo
- Instituto de Investigación Biomédica de Málaga (IBIMA) - Hospital Clínico Universitario Virgen de la Victoria, Málaga, Spain; Centro de Investigación Biomédica en Red de Oncología, CIBERONC, Madrid, Spain; GEICAM, Spanish Breast Cancer Group, Madrid, Spain; Cancer Research UK Cambridge Institute, Li Ka Shing Centre, University of Cambridge, Cambridge, United Kingdom; Hospital Clínico Universitario de Valencia. Biomedical Research Institute INCLIVA. University of Valencia, Valencia, Spain; Hospital del Mar, Barcelona, Spain; Hospital Virgen de la Salud, Toledo, Spain; Complejo Hospitalario Universitario de A Coruña, A Coruña, Spain; Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC) - H. Universitario Reina Sofía, Universidad de Córdoba, Córdoba, Spain; Hospital Clínico Universitario de Valencia, Valencia, Spain; Complejo Hospitalario de Jaén, Jaen, Spain; Onkologikoa, San Sebastián, Spain; Hospital de la Santa Creu i Sant Pau, Barcelona, Spain; Hospital Germans Trias i Pujol, Barcelona, Spai
| | - N Ribelles
- Instituto de Investigación Biomédica de Málaga (IBIMA) - Hospital Clínico Universitario Virgen de la Victoria, Málaga, Spain; Centro de Investigación Biomédica en Red de Oncología, CIBERONC, Madrid, Spain; GEICAM, Spanish Breast Cancer Group, Madrid, Spain; Cancer Research UK Cambridge Institute, Li Ka Shing Centre, University of Cambridge, Cambridge, United Kingdom; Hospital Clínico Universitario de Valencia. Biomedical Research Institute INCLIVA. University of Valencia, Valencia, Spain; Hospital del Mar, Barcelona, Spain; Hospital Virgen de la Salud, Toledo, Spain; Complejo Hospitalario Universitario de A Coruña, A Coruña, Spain; Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC) - H. Universitario Reina Sofía, Universidad de Córdoba, Córdoba, Spain; Hospital Clínico Universitario de Valencia, Valencia, Spain; Complejo Hospitalario de Jaén, Jaen, Spain; Onkologikoa, San Sebastián, Spain; Hospital de la Santa Creu i Sant Pau, Barcelona, Spain; Hospital Germans Trias i Pujol, Barcelona, Spai
| | - P Sánchez-Rovira
- Instituto de Investigación Biomédica de Málaga (IBIMA) - Hospital Clínico Universitario Virgen de la Victoria, Málaga, Spain; Centro de Investigación Biomédica en Red de Oncología, CIBERONC, Madrid, Spain; GEICAM, Spanish Breast Cancer Group, Madrid, Spain; Cancer Research UK Cambridge Institute, Li Ka Shing Centre, University of Cambridge, Cambridge, United Kingdom; Hospital Clínico Universitario de Valencia. Biomedical Research Institute INCLIVA. University of Valencia, Valencia, Spain; Hospital del Mar, Barcelona, Spain; Hospital Virgen de la Salud, Toledo, Spain; Complejo Hospitalario Universitario de A Coruña, A Coruña, Spain; Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC) - H. Universitario Reina Sofía, Universidad de Córdoba, Córdoba, Spain; Hospital Clínico Universitario de Valencia, Valencia, Spain; Complejo Hospitalario de Jaén, Jaen, Spain; Onkologikoa, San Sebastián, Spain; Hospital de la Santa Creu i Sant Pau, Barcelona, Spain; Hospital Germans Trias i Pujol, Barcelona, Spai
| | - A Plazaola
- Instituto de Investigación Biomédica de Málaga (IBIMA) - Hospital Clínico Universitario Virgen de la Victoria, Málaga, Spain; Centro de Investigación Biomédica en Red de Oncología, CIBERONC, Madrid, Spain; GEICAM, Spanish Breast Cancer Group, Madrid, Spain; Cancer Research UK Cambridge Institute, Li Ka Shing Centre, University of Cambridge, Cambridge, United Kingdom; Hospital Clínico Universitario de Valencia. Biomedical Research Institute INCLIVA. University of Valencia, Valencia, Spain; Hospital del Mar, Barcelona, Spain; Hospital Virgen de la Salud, Toledo, Spain; Complejo Hospitalario Universitario de A Coruña, A Coruña, Spain; Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC) - H. Universitario Reina Sofía, Universidad de Córdoba, Córdoba, Spain; Hospital Clínico Universitario de Valencia, Valencia, Spain; Complejo Hospitalario de Jaén, Jaen, Spain; Onkologikoa, San Sebastián, Spain; Hospital de la Santa Creu i Sant Pau, Barcelona, Spain; Hospital Germans Trias i Pujol, Barcelona, Spai
| | - A Barnadas
- Instituto de Investigación Biomédica de Málaga (IBIMA) - Hospital Clínico Universitario Virgen de la Victoria, Málaga, Spain; Centro de Investigación Biomédica en Red de Oncología, CIBERONC, Madrid, Spain; GEICAM, Spanish Breast Cancer Group, Madrid, Spain; Cancer Research UK Cambridge Institute, Li Ka Shing Centre, University of Cambridge, Cambridge, United Kingdom; Hospital Clínico Universitario de Valencia. Biomedical Research Institute INCLIVA. University of Valencia, Valencia, Spain; Hospital del Mar, Barcelona, Spain; Hospital Virgen de la Salud, Toledo, Spain; Complejo Hospitalario Universitario de A Coruña, A Coruña, Spain; Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC) - H. Universitario Reina Sofía, Universidad de Córdoba, Córdoba, Spain; Hospital Clínico Universitario de Valencia, Valencia, Spain; Complejo Hospitalario de Jaén, Jaen, Spain; Onkologikoa, San Sebastián, Spain; Hospital de la Santa Creu i Sant Pau, Barcelona, Spain; Hospital Germans Trias i Pujol, Barcelona, Spai
| | - B Cirauqul
- Instituto de Investigación Biomédica de Málaga (IBIMA) - Hospital Clínico Universitario Virgen de la Victoria, Málaga, Spain; Centro de Investigación Biomédica en Red de Oncología, CIBERONC, Madrid, Spain; GEICAM, Spanish Breast Cancer Group, Madrid, Spain; Cancer Research UK Cambridge Institute, Li Ka Shing Centre, University of Cambridge, Cambridge, United Kingdom; Hospital Clínico Universitario de Valencia. Biomedical Research Institute INCLIVA. University of Valencia, Valencia, Spain; Hospital del Mar, Barcelona, Spain; Hospital Virgen de la Salud, Toledo, Spain; Complejo Hospitalario Universitario de A Coruña, A Coruña, Spain; Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC) - H. Universitario Reina Sofía, Universidad de Córdoba, Córdoba, Spain; Hospital Clínico Universitario de Valencia, Valencia, Spain; Complejo Hospitalario de Jaén, Jaen, Spain; Onkologikoa, San Sebastián, Spain; Hospital de la Santa Creu i Sant Pau, Barcelona, Spain; Hospital Germans Trias i Pujol, Barcelona, Spai
| | - M Ramos
- Instituto de Investigación Biomédica de Málaga (IBIMA) - Hospital Clínico Universitario Virgen de la Victoria, Málaga, Spain; Centro de Investigación Biomédica en Red de Oncología, CIBERONC, Madrid, Spain; GEICAM, Spanish Breast Cancer Group, Madrid, Spain; Cancer Research UK Cambridge Institute, Li Ka Shing Centre, University of Cambridge, Cambridge, United Kingdom; Hospital Clínico Universitario de Valencia. Biomedical Research Institute INCLIVA. University of Valencia, Valencia, Spain; Hospital del Mar, Barcelona, Spain; Hospital Virgen de la Salud, Toledo, Spain; Complejo Hospitalario Universitario de A Coruña, A Coruña, Spain; Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC) - H. Universitario Reina Sofía, Universidad de Córdoba, Córdoba, Spain; Hospital Clínico Universitario de Valencia, Valencia, Spain; Complejo Hospitalario de Jaén, Jaen, Spain; Onkologikoa, San Sebastián, Spain; Hospital de la Santa Creu i Sant Pau, Barcelona, Spain; Hospital Germans Trias i Pujol, Barcelona, Spai
| | - A Arcusa
- Instituto de Investigación Biomédica de Málaga (IBIMA) - Hospital Clínico Universitario Virgen de la Victoria, Málaga, Spain; Centro de Investigación Biomédica en Red de Oncología, CIBERONC, Madrid, Spain; GEICAM, Spanish Breast Cancer Group, Madrid, Spain; Cancer Research UK Cambridge Institute, Li Ka Shing Centre, University of Cambridge, Cambridge, United Kingdom; Hospital Clínico Universitario de Valencia. Biomedical Research Institute INCLIVA. University of Valencia, Valencia, Spain; Hospital del Mar, Barcelona, Spain; Hospital Virgen de la Salud, Toledo, Spain; Complejo Hospitalario Universitario de A Coruña, A Coruña, Spain; Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC) - H. Universitario Reina Sofía, Universidad de Córdoba, Córdoba, Spain; Hospital Clínico Universitario de Valencia, Valencia, Spain; Complejo Hospitalario de Jaén, Jaen, Spain; Onkologikoa, San Sebastián, Spain; Hospital de la Santa Creu i Sant Pau, Barcelona, Spain; Hospital Germans Trias i Pujol, Barcelona, Spai
| | - E Carrasco
- Instituto de Investigación Biomédica de Málaga (IBIMA) - Hospital Clínico Universitario Virgen de la Victoria, Málaga, Spain; Centro de Investigación Biomédica en Red de Oncología, CIBERONC, Madrid, Spain; GEICAM, Spanish Breast Cancer Group, Madrid, Spain; Cancer Research UK Cambridge Institute, Li Ka Shing Centre, University of Cambridge, Cambridge, United Kingdom; Hospital Clínico Universitario de Valencia. Biomedical Research Institute INCLIVA. University of Valencia, Valencia, Spain; Hospital del Mar, Barcelona, Spain; Hospital Virgen de la Salud, Toledo, Spain; Complejo Hospitalario Universitario de A Coruña, A Coruña, Spain; Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC) - H. Universitario Reina Sofía, Universidad de Córdoba, Córdoba, Spain; Hospital Clínico Universitario de Valencia, Valencia, Spain; Complejo Hospitalario de Jaén, Jaen, Spain; Onkologikoa, San Sebastián, Spain; Hospital de la Santa Creu i Sant Pau, Barcelona, Spain; Hospital Germans Trias i Pujol, Barcelona, Spai
| | - J Herranz
- Instituto de Investigación Biomédica de Málaga (IBIMA) - Hospital Clínico Universitario Virgen de la Victoria, Málaga, Spain; Centro de Investigación Biomédica en Red de Oncología, CIBERONC, Madrid, Spain; GEICAM, Spanish Breast Cancer Group, Madrid, Spain; Cancer Research UK Cambridge Institute, Li Ka Shing Centre, University of Cambridge, Cambridge, United Kingdom; Hospital Clínico Universitario de Valencia. Biomedical Research Institute INCLIVA. University of Valencia, Valencia, Spain; Hospital del Mar, Barcelona, Spain; Hospital Virgen de la Salud, Toledo, Spain; Complejo Hospitalario Universitario de A Coruña, A Coruña, Spain; Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC) - H. Universitario Reina Sofía, Universidad de Córdoba, Córdoba, Spain; Hospital Clínico Universitario de Valencia, Valencia, Spain; Complejo Hospitalario de Jaén, Jaen, Spain; Onkologikoa, San Sebastián, Spain; Hospital de la Santa Creu i Sant Pau, Barcelona, Spain; Hospital Germans Trias i Pujol, Barcelona, Spai
| | - M Chiesa
- Instituto de Investigación Biomédica de Málaga (IBIMA) - Hospital Clínico Universitario Virgen de la Victoria, Málaga, Spain; Centro de Investigación Biomédica en Red de Oncología, CIBERONC, Madrid, Spain; GEICAM, Spanish Breast Cancer Group, Madrid, Spain; Cancer Research UK Cambridge Institute, Li Ka Shing Centre, University of Cambridge, Cambridge, United Kingdom; Hospital Clínico Universitario de Valencia. Biomedical Research Institute INCLIVA. University of Valencia, Valencia, Spain; Hospital del Mar, Barcelona, Spain; Hospital Virgen de la Salud, Toledo, Spain; Complejo Hospitalario Universitario de A Coruña, A Coruña, Spain; Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC) - H. Universitario Reina Sofía, Universidad de Córdoba, Córdoba, Spain; Hospital Clínico Universitario de Valencia, Valencia, Spain; Complejo Hospitalario de Jaén, Jaen, Spain; Onkologikoa, San Sebastián, Spain; Hospital de la Santa Creu i Sant Pau, Barcelona, Spain; Hospital Germans Trias i Pujol, Barcelona, Spai
| | - R Caballero
- Instituto de Investigación Biomédica de Málaga (IBIMA) - Hospital Clínico Universitario Virgen de la Victoria, Málaga, Spain; Centro de Investigación Biomédica en Red de Oncología, CIBERONC, Madrid, Spain; GEICAM, Spanish Breast Cancer Group, Madrid, Spain; Cancer Research UK Cambridge Institute, Li Ka Shing Centre, University of Cambridge, Cambridge, United Kingdom; Hospital Clínico Universitario de Valencia. Biomedical Research Institute INCLIVA. University of Valencia, Valencia, Spain; Hospital del Mar, Barcelona, Spain; Hospital Virgen de la Salud, Toledo, Spain; Complejo Hospitalario Universitario de A Coruña, A Coruña, Spain; Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC) - H. Universitario Reina Sofía, Universidad de Córdoba, Córdoba, Spain; Hospital Clínico Universitario de Valencia, Valencia, Spain; Complejo Hospitalario de Jaén, Jaen, Spain; Onkologikoa, San Sebastián, Spain; Hospital de la Santa Creu i Sant Pau, Barcelona, Spain; Hospital Germans Trias i Pujol, Barcelona, Spai
| | - A Santonja
- Instituto de Investigación Biomédica de Málaga (IBIMA) - Hospital Clínico Universitario Virgen de la Victoria, Málaga, Spain; Centro de Investigación Biomédica en Red de Oncología, CIBERONC, Madrid, Spain; GEICAM, Spanish Breast Cancer Group, Madrid, Spain; Cancer Research UK Cambridge Institute, Li Ka Shing Centre, University of Cambridge, Cambridge, United Kingdom; Hospital Clínico Universitario de Valencia. Biomedical Research Institute INCLIVA. University of Valencia, Valencia, Spain; Hospital del Mar, Barcelona, Spain; Hospital Virgen de la Salud, Toledo, Spain; Complejo Hospitalario Universitario de A Coruña, A Coruña, Spain; Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC) - H. Universitario Reina Sofía, Universidad de Córdoba, Córdoba, Spain; Hospital Clínico Universitario de Valencia, Valencia, Spain; Complejo Hospitalario de Jaén, Jaen, Spain; Onkologikoa, San Sebastián, Spain; Hospital de la Santa Creu i Sant Pau, Barcelona, Spain; Hospital Germans Trias i Pujol, Barcelona, Spai
| | - F Rojo
- Instituto de Investigación Biomédica de Málaga (IBIMA) - Hospital Clínico Universitario Virgen de la Victoria, Málaga, Spain; Centro de Investigación Biomédica en Red de Oncología, CIBERONC, Madrid, Spain; GEICAM, Spanish Breast Cancer Group, Madrid, Spain; Cancer Research UK Cambridge Institute, Li Ka Shing Centre, University of Cambridge, Cambridge, United Kingdom; Hospital Clínico Universitario de Valencia. Biomedical Research Institute INCLIVA. University of Valencia, Valencia, Spain; Hospital del Mar, Barcelona, Spain; Hospital Virgen de la Salud, Toledo, Spain; Complejo Hospitalario Universitario de A Coruña, A Coruña, Spain; Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC) - H. Universitario Reina Sofía, Universidad de Córdoba, Córdoba, Spain; Hospital Clínico Universitario de Valencia, Valencia, Spain; Complejo Hospitalario de Jaén, Jaen, Spain; Onkologikoa, San Sebastián, Spain; Hospital de la Santa Creu i Sant Pau, Barcelona, Spain; Hospital Germans Trias i Pujol, Barcelona, Spai
| | - C Caldas
- Instituto de Investigación Biomédica de Málaga (IBIMA) - Hospital Clínico Universitario Virgen de la Victoria, Málaga, Spain; Centro de Investigación Biomédica en Red de Oncología, CIBERONC, Madrid, Spain; GEICAM, Spanish Breast Cancer Group, Madrid, Spain; Cancer Research UK Cambridge Institute, Li Ka Shing Centre, University of Cambridge, Cambridge, United Kingdom; Hospital Clínico Universitario de Valencia. Biomedical Research Institute INCLIVA. University of Valencia, Valencia, Spain; Hospital del Mar, Barcelona, Spain; Hospital Virgen de la Salud, Toledo, Spain; Complejo Hospitalario Universitario de A Coruña, A Coruña, Spain; Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC) - H. Universitario Reina Sofía, Universidad de Córdoba, Córdoba, Spain; Hospital Clínico Universitario de Valencia, Valencia, Spain; Complejo Hospitalario de Jaén, Jaen, Spain; Onkologikoa, San Sebastián, Spain; Hospital de la Santa Creu i Sant Pau, Barcelona, Spain; Hospital Germans Trias i Pujol, Barcelona, Spai
| |
Collapse
|
20
|
Quiroga V, Holgado E, Alonso J, Andres R, Moreno Anton F, Alamo De La Gala M, Henao F, Cirauqui Cirauqui B, Margeli M, Cortes Castan J, Gion Cortes M, Soto A, Benito S, Escudero M, Chiesa M, Caballero R, Bezares Montes S, Carrasco E, De La Cruz Merino L. Run-in-phase results from a multicenter phase II trial to evaluate pembrolizumab (P) and gemcitabine (Gem) in patients (pts) with HER2-negative advanced breast cancer (ABC): GEICAM/2015-04 PANGEA-Breast. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy487.019] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
21
|
Gioffre' S, Chiesa M, Alfieri I, Masson S, Latini R, Sandri MT, Cardinale D, Pompilio G, Colombo GI, D'Alessandra Y. P4763Circulating microRNAs as selective markers of anthracyclines-based therapies in breast cancer patients. Eur Heart J 2018. [DOI: 10.1093/eurheartj/ehy563.p4763] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Affiliation(s)
- S Gioffre'
- Cardiology Center Monzino IRCCS, Milan, Italy
| | - M Chiesa
- Cardiology Center Monzino IRCCS, Milan, Italy
| | - I Alfieri
- Cardiology Center Monzino IRCCS, Milan, Italy
| | - S Masson
- The Mario Negri Institute for Pharmacological Research, Milan, Italy
| | - R Latini
- The Mario Negri Institute for Pharmacological Research, Milan, Italy
| | - M T Sandri
- Cardiology Center Monzino IRCCS, Milan, Italy
| | - D Cardinale
- Cardiology Center Monzino IRCCS, Milan, Italy
| | - G Pompilio
- Cardiology Center Monzino IRCCS, Milan, Italy
| | - G I Colombo
- Cardiology Center Monzino IRCCS, Milan, Italy
| | | |
Collapse
|
22
|
Songia P, Chiesa M, Myasoedova V, Gripari P, Valerio V, Montanari S, Moschetta D, Pepi M, Colombo GI, Baldassarre D, Poggio P. P5448Patients with aortic valve sclerosis show a different circulating miRNA profile compared to healthy subjects. Eur Heart J 2018. [DOI: 10.1093/eurheartj/ehy566.p5448] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Affiliation(s)
- P Songia
- Cardiology Center Monzino IRCCS, Milan, Italy
| | - M Chiesa
- Cardiology Center Monzino IRCCS, Milan, Italy
| | | | - P Gripari
- Cardiology Center Monzino IRCCS, Milan, Italy
| | - V Valerio
- Cardiology Center Monzino IRCCS, Milan, Italy
| | - S Montanari
- Cardiology Center Monzino IRCCS, Milan, Italy
| | - D Moschetta
- Cardiology Center Monzino IRCCS, Milan, Italy
| | - M Pepi
- Cardiology Center Monzino IRCCS, Milan, Italy
| | - G I Colombo
- Cardiology Center Monzino IRCCS, Milan, Italy
| | | | - P Poggio
- Cardiology Center Monzino IRCCS, Milan, Italy
| |
Collapse
|
23
|
D'Alessandra Y, Gioffre' S, Chiesa M, Piacentini L, Ruggeri C, D'Avila F, Ricci V, Vavassori C, Castiglioni L, Sironi L, Scopece A, Milano G, Pompilio G, Colombo GI. P2848Long-term specific transcriptional effects of doxorubicin-induced cardiotoxicity on distinct murine cardiac chambers. Eur Heart J 2018. [DOI: 10.1093/eurheartj/ehy565.p2848] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Affiliation(s)
| | - S Gioffre'
- Cardiology Center Monzino IRCCS, Milan, Italy
| | - M Chiesa
- Cardiology Center Monzino IRCCS, Milan, Italy
| | | | - C Ruggeri
- Cardiology Center Monzino IRCCS, Milan, Italy
| | - F D'Avila
- Cardiology Center Monzino IRCCS, Milan, Italy
| | - V Ricci
- Cardiology Center Monzino IRCCS, Milan, Italy
| | - C Vavassori
- Cardiology Center Monzino IRCCS, Milan, Italy
| | | | - L Sironi
- University of Milan, Milan, Italy
| | - A Scopece
- Cardiology Center Monzino IRCCS, Milan, Italy
| | - G Milano
- Cardiology Center Monzino IRCCS, Milan, Italy
| | - G Pompilio
- Cardiology Center Monzino IRCCS, Milan, Italy
| | - G I Colombo
- Cardiology Center Monzino IRCCS, Milan, Italy
| |
Collapse
|
24
|
D'Alessandra Y, Gioffre' S, Chiesa M, Piacentini L, D'Avila F, Ruggeri C, Vavassori C, Ricci V, Castiglioni L, Scopece A, Milano G, Marenzi G, Pompilio G, Colombo GI. P925Cardiac injury-induced regulation of clock genes: lessons from mice and patients. Eur Heart J 2018. [DOI: 10.1093/eurheartj/ehy564.p925] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Affiliation(s)
| | - S Gioffre'
- Cardiology Center Monzino IRCCS, Milan, Italy
| | - M Chiesa
- Cardiology Center Monzino IRCCS, Milan, Italy
| | | | - F D'Avila
- Cardiology Center Monzino IRCCS, Milan, Italy
| | - C Ruggeri
- Cardiology Center Monzino IRCCS, Milan, Italy
| | - C Vavassori
- Cardiology Center Monzino IRCCS, Milan, Italy
| | - V Ricci
- Cardiology Center Monzino IRCCS, Milan, Italy
| | | | - A Scopece
- Cardiology Center Monzino IRCCS, Milan, Italy
| | - G Milano
- Cardiology Center Monzino IRCCS, Milan, Italy
| | - G Marenzi
- Cardiology Center Monzino IRCCS, Milan, Italy
| | - G Pompilio
- Cardiology Center Monzino IRCCS, Milan, Italy
| | - G I Colombo
- Cardiology Center Monzino IRCCS, Milan, Italy
| |
Collapse
|
25
|
Poggio P, Songia P, Chiesa M, Barbieri S, Moschetta D, Valerio V, Cavallotti L, Ferri N, Zanotti I, Camera M. P5091Involvement of proprotein convertase subtilisin/kexin type 9 (PCSK9) in aortic valvular calcification. Eur Heart J 2018. [DOI: 10.1093/eurheartj/ehy566.p5091] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Affiliation(s)
- P Poggio
- Cardiology Center Monzino IRCCS, Milan, Italy
| | - P Songia
- Cardiology Center Monzino IRCCS, Milan, Italy
| | - M Chiesa
- Cardiology Center Monzino IRCCS, Milan, Italy
| | - S Barbieri
- Cardiology Center Monzino IRCCS, Milan, Italy
| | - D Moschetta
- Cardiology Center Monzino IRCCS, Milan, Italy
| | - V Valerio
- Cardiology Center Monzino IRCCS, Milan, Italy
| | | | - N Ferri
- University of Padova, Padua, Italy
| | | | - M Camera
- Cardiology Center Monzino IRCCS, Milan, Italy
| |
Collapse
|
26
|
Colombo GI, Chiesa M, Piacentini L, Bono E, Milazzo V, Marenzi G. P2716Blood-based transcriptional biomarkers of STEMI and NSTEMI. Eur Heart J 2018. [DOI: 10.1093/eurheartj/ehy565.p2716] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Affiliation(s)
- G I Colombo
- Centro Cardiologico Monzino IRCCS, Unit of Immunology and Functional Genomics, Milano, Italy
| | - M Chiesa
- Centro Cardiologico Monzino IRCCS, Unit of Immunology and Functional Genomics, Milano, Italy
| | - L Piacentini
- Centro Cardiologico Monzino IRCCS, Unit of Immunology and Functional Genomics, Milano, Italy
| | - E Bono
- Centro Cardiologico Monzino IRCCS, Unit of Immunology and Functional Genomics, Milano, Italy
| | - V Milazzo
- Centro Cardiologico Monzino IRCCS, Intensive Cardiac Care Unit, Milano, Italy
| | - G Marenzi
- Centro Cardiologico Monzino IRCCS, Intensive Cardiac Care Unit, Milano, Italy
| |
Collapse
|
27
|
de la Cruz-Merino L, Palazón-Carrión N, Henao-Carrasco F, Nogales-Fernández E, Álamo-de la Gala M, Vallejo-Benítez A, Chiesa M, Sánchez-Margalet V. New horizons in breast cancer: the promise of immunotherapy. Clin Transl Oncol 2018; 21:117-125. [PMID: 29916188 DOI: 10.1007/s12094-018-1907-3] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/28/2018] [Accepted: 06/04/2018] [Indexed: 12/29/2022]
Abstract
Immunology and immunotherapy of cancer is an expanding field in oncology, with recent great achievements obtained through the new successful approaches implemented to circumvent immune evasion, which is undoubtedly considered a novel hallmark of cancer. Translational research in this topic has revealed targets that can be modulated in the clinical setting with new compounds and strategies. Like most of the tumors, breast cancer is considered a complex and heterogeneous disease in which host immune responses have been also recently demonstrated of critical relevance. T infiltrating lymphocyte measurement is suggested as a powerful new tool necessary to predict early breast cancer evolution, especially for the her2-positive and triple-negative subtypes. Other biomarkers in tissue and peripheral blood are under intense scrutiny to ascertain their eventual role as prognostic and/or predictive factors. This background has fueled the interest in developing clinical research strategies to test activity of modern immunotherapy in breast cancer, which constitutes the main focus of this review.
Collapse
Affiliation(s)
- L de la Cruz-Merino
- Clinical Oncology Department, Hospital Universitario Virgen Macarena, Avda Dr Fedriani s/n, 41009, Seville, Spain.
| | - N Palazón-Carrión
- Clinical Oncology Department, Hospital Universitario Virgen Macarena, Avda Dr Fedriani s/n, 41009, Seville, Spain
| | - F Henao-Carrasco
- Clinical Oncology Department, Hospital Universitario Virgen Macarena, Avda Dr Fedriani s/n, 41009, Seville, Spain
| | - E Nogales-Fernández
- Clinical Oncology Department, Hospital Universitario Virgen Macarena, Avda Dr Fedriani s/n, 41009, Seville, Spain
| | - M Álamo-de la Gala
- Clinical Oncology Department, Hospital Universitario Virgen Macarena, Avda Dr Fedriani s/n, 41009, Seville, Spain
| | - A Vallejo-Benítez
- Pathology Department, Hospital Universitario Virgen Macarena, Avda Dr Fedriani s/n, 41009, Seville, Spain
| | - M Chiesa
- Spanish Breast Cancer Research Group (GEICAM), 28703, Madrid, Spain
| | - V Sánchez-Margalet
- Department of Medical Biochemistry and Molecular Biology and Immunology, Medical School, Hospital Universitario Virgen Macarena, Avda Dr Fedriani s/n, 41009, Seville, Spain
| | | |
Collapse
|
28
|
Alba E, Rueda OM, Lluch A, Albanell J, Chin SF, Chacon JI, Calvo L, De La Haba J, Bermejo B, Ribelles N, Cirauqui B, Ramos Vazquez M, Arcusa Lanza MA, Carrasco EM, Herranz J, Chiesa M, Caballero R, Santonja Climent A, Rojo F, Caldas C. Integrative cluster classification to predict pathological complete response to neoadjuvant chemotherapy in early breast cancer. J Clin Oncol 2018. [DOI: 10.1200/jco.2018.36.15_suppl.579] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- Emilio Alba
- Hospital Clínico Universitario Virgen de la Victoria. GEICAM Spanish Breast Cancer Group., Malaga, Spain
| | - Oscar M Rueda
- Cancer Research UK Cambridge Institute, Cambridge, United Kingdom
| | - Ana Lluch
- Hospital Clinico Universitario de Valencia; Centro de Investigación Biomédica en Red de Oncología; CIBERONC-ISCIII; GEICAM Spanish Breast Cancer Group, Valencia, Spain
| | - Joan Albanell
- Hospital del Mar; GEICAM Spanish Breast Cancer Group, Barcelona, Spain
| | - Suet-Feung Chin
- Cancer Research UK, Cambridge Research Institute, Cambridge, United Kingdom
| | - Jose Ignacio Chacon
- Hospital Virgen de la Salud; GEICAM Spanish Breast Cancer Group, Toledo, Spain
| | - Lourdes Calvo
- Complejo Hospitalario Universitario de A Coruña. GEICAM Spanish Breast Cancer Group., A Coruna, Spain
| | - Juan De La Haba
- Biomedical Research Institute Maimonides.Hospital UniversitarioReina Sofia,Universidad de Cordoba, Spain.Centro de Investigación Biomédica en Red de Oncología, CIBERONC-ISCIII. GEICAM, Spanish Breast Cancer Group, Spain, Cordoba, Spain
| | - Begona Bermejo
- Hospital Clinico Universitario de Valencia; Centro de Investigación Biomédica en Red de Oncología; CIBERONC-ISCIII; GEICAM Spanish Breast Cancer Group, Valencia, Spain
| | - Nuria Ribelles
- IBIMA, Unidad de Gestión Clínica Intercentros de Oncología, Hospitales Universitarios Regional y Virgen de la Victoria de Málaga, Malaga, Spain
| | - Beatriz Cirauqui
- Medical Oncology Department. Catalan Institute of Oncology, Hospital Germans Trias i Pujol, Badalona, Spain
| | - Manuel Ramos Vazquez
- Centro Oncológico de Galicia. GEICAM Spanish Breast Cancer Group., A Coruña, Spain
| | | | | | | | | | | | | | - Federico Rojo
- Fundación Jiménez Díaz,Madrid.Centro de Investigación Biomédica en Red de Oncología, Centro de Investigación Biomédica en Red de Oncología, CIBERONC-ISCIII, Madrid, Spain
| | - Carlos Caldas
- Cancer Research UK Cambridge Institute, Li Ka Shing Centre, University of Cambridge, Cambridge, United Kingdom
| |
Collapse
|
29
|
Alba E, Rueda OM, Lluch A, Albanell J, Chin SF, Chacon JI, Calvo L, De La Haba J, Bermejo B, Ribelles N, Sanchez Rovira P, Plazaola A, Barnadas A, Carrasco EM, Herranz J, Chiesa M, Caballero R, Santonja Climent A, Rojo F, Caldas C. Dynamic genomic instability modulation by neoadjuvant therapy in early breast cancer (GEICAM/2006-03_2006-14). J Clin Oncol 2018. [DOI: 10.1200/jco.2018.36.15_suppl.592] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- Emilio Alba
- Hospital Clínico Universitario Virgen de la Victoria. GEICAM Spanish Breast Cancer Group., Malaga, Spain
| | - Oscar M Rueda
- Cancer Research UK Cambridge Institute, Cambridge, United Kingdom
| | - Ana Lluch
- Hospital Clinico Universitario de Valencia; Centro de Investigación Biomédica en Red de Oncología; CIBERONC-ISCIII; GEICAM Spanish Breast Cancer Group, Valencia, Spain
| | - Joan Albanell
- Hospital del Mar; GEICAM Spanish Breast Cancer Group, Barcelona, Spain
| | - Suet-Feung Chin
- Cancer Research UK, Cambridge Research Institute, Cambridge, United Kingdom
| | - Jose Ignacio Chacon
- Hospital Virgen de la Salud; GEICAM Spanish Breast Cancer Group, Toledo, Spain
| | - Lourdes Calvo
- Complejo Hospitalario Universitario de A Coruña. GEICAM Spanish Breast Cancer Group., A Coruna, Spain
| | - Juan De La Haba
- Biomedical Research Institute Maimonides.Hospital UniversitarioReina Sofia,Universidad de Cordoba, Spain.Centro de Investigación Biomédica en Red de Oncología, CIBERONC-ISCIII. GEICAM, Spanish Breast Cancer Group, Spain, Cordoba, Spain
| | - Begona Bermejo
- Hospital Clinico Universitario de Valencia; Centro de Investigación Biomédica en Red de Oncología; CIBERONC-ISCIII; GEICAM Spanish Breast Cancer Group, Valencia, Spain
| | - Nuria Ribelles
- IBIMA, Unidad de Gestión Clínica Intercentros de Oncología, Hospitales Universitarios Regional y Virgen de la Victoria de Málaga, Malaga, Spain
| | | | - Arrate Plazaola
- Onkologikoa. GEICAM Spanish Breast Cancer Group., San Sebastian-Donostia, Spain
| | - Agusti Barnadas
- Hospital de la Santa Creu i Sant Pau, Barcelona; Centro de Investigación Biomédica en Red de Oncología, CIBERONC-ISCIII; GEICAM Spanish Breast Cancer Group, Barcelona, Spain
| | | | | | | | | | | | - Federico Rojo
- Fundación Jiménez Díaz,Madrid.Centro de Investigación Biomédica en Red de Oncología, Centro de Investigación Biomédica en Red de Oncología, CIBERONC-ISCIII, Madrid, Spain
| | - Carlos Caldas
- Cancer Research UK Cambridge Institute, Li Ka Shing Centre, University of Cambridge, Cambridge, United Kingdom
| |
Collapse
|
30
|
De Pedro N, Estrada J, Chiesa M, Diez M, Garcia I, González R, Garcia B, García J, Esteban L, Otero L, Najarro P. Telomere associated variables and their potential in CLL prognosis. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx363.014] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
31
|
Zara C, D'Alessandro R, Brambilla M, Chiesa M, Tremoli E, Camera M. P6043Single cell transcriptome analysis in living human platelets from healthy subjects and CAD patients. Eur Heart J 2017. [DOI: 10.1093/eurheartj/ehx493.p6043] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
32
|
Herraiz Lablanca M, Paul S, Chiesa M, Grosser K, Harms W. PO-1006: Evaluation of an auto-segmentation software for definition of organs at risk in radiotherapy. Radiother Oncol 2017. [DOI: 10.1016/s0167-8140(17)31442-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
33
|
Moreno-González M, Palomares AE, Chiesa M, Boronat M, Giamello E, Blasco T. Evidence of a Cu2+–Alkane Interaction in Cu-Zeolite Catalysts Crucial for the Selective Catalytic Reduction of NOx with Hydrocarbons. ACS Catal 2017. [DOI: 10.1021/acscatal.6b03473] [Citation(s) in RCA: 22] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Affiliation(s)
- M. Moreno-González
- Instituto
de Tecnología Química, Universitat Politècnica de València-Consejo Superior de Investigaciones Científicas (UPV-CSIC), Avda. de los Naranjos s/n, 46022 Valencia, Spain
| | - A. E. Palomares
- Instituto
de Tecnología Química, Universitat Politècnica de València-Consejo Superior de Investigaciones Científicas (UPV-CSIC), Avda. de los Naranjos s/n, 46022 Valencia, Spain
| | - M. Chiesa
- Dipartimento
di Chimica, Università di Torino, Via Giuria, 7, 10125 Torino, Italy
| | - M. Boronat
- Instituto
de Tecnología Química, Universitat Politècnica de València-Consejo Superior de Investigaciones Científicas (UPV-CSIC), Avda. de los Naranjos s/n, 46022 Valencia, Spain
| | - E. Giamello
- Dipartimento
di Chimica, Università di Torino, Via Giuria, 7, 10125 Torino, Italy
| | - T. Blasco
- Instituto
de Tecnología Química, Universitat Politècnica de València-Consejo Superior de Investigaciones Científicas (UPV-CSIC), Avda. de los Naranjos s/n, 46022 Valencia, Spain
| |
Collapse
|
34
|
Colombo M, Mirando M, Rattalino D, Beltrami R, Chiesa M, Poggio C. Remineralizing effect of a zinc-hydroxyapatite toothpaste on enamel erosion caused by soft drinks: Ultrastructural analysis. J Clin Exp Dent 2017; 9:e861-e868. [PMID: 28828151 PMCID: PMC5553346 DOI: 10.4317/jced.53790] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/17/2017] [Accepted: 05/27/2017] [Indexed: 11/05/2022] Open
Abstract
Background Material and Methods Results Conclusions
Collapse
|
35
|
de la Cruz-Merino L, Chiesa M, Caballero R, Rojo F, Palazón N, Carrasco FH, Sánchez-Margalet V. Breast Cancer Immunology and Immunotherapy: Current Status and Future Perspectives. Int Rev Cell Mol Biol 2016; 331:1-53. [PMID: 28325210 DOI: 10.1016/bs.ircmb.2016.09.008] [Citation(s) in RCA: 34] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
Abstract
Cancer immunology has gained renewed interest in the past few years due to emerging findings on mechanisms involved in tumoral immune evasion. Indisputably, immune edition is currently considered a critical hallmark of cancer. Basic research has revealed new targets which can be modulated in the clinical setting with new compounds and strategies. As recent evidence confirms, breast cancer (BC) is a complex and heterogeneous disease in which host immune responses play a substantial role. T-infiltrating lymphocytes measurement is suggested as a powerful new tool necessary to predict early BC evolution, especially in HER2-positive and triple negative subtypes. However, T-infiltrating lymphocytes, genomic platforms, and many other biomarkers in tissue and peripheral blood (e.g., regulatory T cells and myeloid-derived suppressor cells) are not the only factors being evaluated regarding their potential role as prognostic and/or predictive factors. Many ongoing clinical trials are exploring the activity of immune checkpoint modulators in BC treatment, both in the advanced and neoadjuvant setting. Although this field is expanding with exciting new discoveries and promising clinical results-and creating great expectations-there remain many uncertainties yet to be addressed satisfactorily before this long awaited therapeutic promise can come to fruition.
Collapse
Affiliation(s)
| | - M Chiesa
- GEICAM (Spanish Breast Cancer Research Group), Madrid, Spain
| | - R Caballero
- GEICAM (Spanish Breast Cancer Research Group), Madrid, Spain
| | - F Rojo
- Fundación Jiménez Díaz, Madrid, Spain
| | - N Palazón
- GEICAM (Spanish Breast Cancer Research Group), Madrid, Spain
| | - F H Carrasco
- GEICAM (Spanish Breast Cancer Research Group), Madrid, Spain
| | | |
Collapse
|
36
|
Garcia-Martinez V, Lopez Sanchez C, Hamed W, Hamed W, Hsu JH, Ferrer-Lorente R, Alshamrani M, Pizzicannella J, Vindis C, Badi I, Korte L, Voellenkle C, Niculescu LS, Massaro M, Babaeva AR, Da Silva F, Woudstra L, Berezin A, Bae MK, Del Giudice C, Bageghni SA, Krobert K, Levay M, Vignier N, Ranieri A, Magenta A, Orlandi A, Porro B, Jeon ES, Omori Y, Herold J, Barnett GA, Grochot-Przeczek A, Korpisalo P, Deffge C, Margariti A, Rong W, Maring JA, Gambardella J, Mitrofan CG, Karpinska O, Morbidelli L, Wilkinson FL, Berezin A, Kostina AS, De Mey JGR, Kumar A, Lupieri A, Pellet-Many C, Stamatiou R, Gromotowicz A, Dickhout A, Murina M, Roka-Moiia YM, Malinova L, Diaz-Canestro C, Vigliarolo T, Cuzzocrea S, Szantai A, Medic B, Cassambai S, Korda A, Revnic CR, Borile G, Diokmetzidou A, Murfitt L, Budko A, Fiordelisi A, De Wijs-Meijler DPM, Gevaert AB, Noriega De La Colina A, Benes J, Guillermo Solache Berrocal GSB, Gafarov V, Zhebel VM, Prakaschandra R, Stepien EL, Smith LE, Carluccio MA, Timasheva Y, Paci M, Dorofeyeva NA, Chimed CH, Petelina TI, Sorop O, Genis A, Parepa IR, Tscharre M, Krestjyaninov MV, Maia-Rocha C, Borges L, Sasonko ML, Kapel SS, Stam K, Sommariva E, Stojkovic S, O'reilly J, Chiva-Blanch G, Malinova L, Evtushenko A, Skopal J, Sunderland N, Gegenava T, Charnaia MA, Di Lascio N, Tarvainen SJ, Malandraki-Miller S, Uitterdijk A, Benzoni P, Ruivo E, Humphrey EJ, Arokiaraj MC, Franco D, Garcia-Lopez V, Aranega A, Lopez-Sanchez C, Franco D, Garcia-Lopez V, Aranega A, Garcia-Martinez V, Tayel S, Khader H, El-Helbawy N, Tayel S, Alrefai A, El-Barbary H, Wu JR, Dai ZK, Yeh JL, Sanjurjo-Rodriguez C, Richaud-Patin Y, Blanco FJ, Badimon L, Raya A, Cahill PA, Diomede F, Merciaro I, Trubiani O, Nahapetyan H, Swiader A, Faccini J, Boya P, Elbaz M, Zeni F, Burba I, Bertolotti M, Capogrossi MC, Pompilio G, Raucci A, Widmer-Teske R, Dutzmann J, Bauersachs J, Donde K, Daniel JM, Sedding DG, Simionescu N, Sanda GM, Carnuta MG, Stancu CS, Popescu AC, Popescu MR, Vlad A, Dimulescu DR, Sima AV, Scoditti E, Pellegrino M, Calabriso N, Carluccio MA, Storelli C, De Caterina R, Solodenkova KS, Kalinina EV, Usachiova MN, Lappalainen J, Lee-Rueckert MDEC, Kovanen PT, Biesbroek PS, Emmens RWE, Van Rossum AC, Juffermans LJM, Niessen JWM, Krijnen PAJ, Kremzer A, Samura T, Berezina T, Gronenko E, Kim MK, Park HJ, Bae SK, Sorriento D, Ciccarelli M, Vernieri E, Campiglia P, Trimarco B, Iaccarino G, Hemmings KE, Porter KE, Ainscough JF, Drinkhill MJ, Turner NA, Hiis HG, Cosson MV, Levy FO, Wieland T, Macquart C, Chatzifrangkeskou M, Evans A, Bonne G, Muchir A, Kemp E, Avkiran M, Carlomosti F, D'agostino M, Beji S, Zaccagnini G, Maimone B, Di Stefano V, De Santa F, Cordisco S, Antonini A, Ciarapica R, Dellambra E, Martelli F, Avitabile D, Capogrossi MC, Scioli MG, Bielli A, Agostinelli S, Tarquini C, Tarallo V, De Falco S, Zaninoni A, Fiorelli S, Bianchi P, Teruzzi G, Squellerio I, Turnu L, Lualdi A, Tremoli E, Cavalca V, Lee YJ, Ju ES, Choi JO, Lee GY, Lim BK, Manickam MANOJ, Jung SH, Omiya S, Otsu K, Deffge C, Nowak S, Wagner M, Braun-Dullaeus RC, Kostin S, Daniel JM, Francke A, Subramaniam S, Kanse SM, Al-Lamee K, Schofield CJ, Egginton S, Gershlick AH, Kloska D, Kopacz A, Augustyniak A, Dulak J, Jozkowicz A, Hytonen J, Halonen P, Taavitsainen J, Tarvainen S, Hiltunen T, Liimatainen T, Kalliokoski K, Knuuti J, Yla-Herttuala S, Wagner M, Weinert S, Isermann B, Lee J, Braun-Dullaeus RC, Herold J, Cochrane A, Kelaini S, Bojdo J, Vila Gonzalez M, Hu Y, Grieve D, Stitt AW, Zeng L, Xu Q, Margariti A, Reglin B, Xiang W, Nitzsche B, Maibier M, Pries AR, Vrijsen KR, Chamuleau SAJ, Verhage V, Metz CHG, Lodder K, Van Eeuwijk ECM, Van Dommelen SM, Doevendans PA, Smits AM, Goumans MJ, Sluijter JPG, Sorriento D, Bova M, Loffredo S, Trimarco B, Iaccarino G, Ciccarelli M, Appleby S, Morrell N, Baranowska-Kuczko M, Kloza M, Ambrozewicz E, Kozlowski M, Malinowska B, Kozlowska H, Monti M, Terzuoli E, Ziche M, Mahmoud AM, Jones AM, Wilkinson JA, Romero M, Duarte J, Alexander MY, Kremzer A, Berezina T, Gronenko E, Faggian G, Kostareva AA, Malashicheva AB, Leurgans TM, Nguyen TN, Irmukhamedov A, Riber LP, Mcgeogh R, Comer S, Blanco Fernandez A, Ghigo A, Blaise R, Smirnova NF, Malet N, Vincent P, Limon I, Gayral S, Hirsch E, Laffargue M, Mehta V, Zachary I, Aidonidis I, Kramkowski K, Miltyk W, Kolodziejczyk P, Gradzka A, Szemraj J, Chabielska E, Dijkgraaf I, Bitsch N, Van Hoof S, Verhaegen F, Koenen R, Hackeng TM, Roshchupkin DI, Buravleva KV, Sergienko VI, Zhernossekov DD, Rybachuk VM, Grinenko TV, Furman N, Dolotovskaya P, Shamyunov M, Denisova T, Reiner M, Akhmedov A, Keller S, Miranda M, Briand S, Barile L, Kullak-Ublick G, Luscher T, Camici G, Guida L, Magnone M, Ameri P, Lazzarini E, Fresia C, Bruzzone S, Zocchi E, Di Paola R, Cordaro M, Crupi R, Siracusa R, Campolo M, Bruschetta G, Fusco R, Pugliatti P, Esposito E, Paloczi J, Ruivo E, Gaspar R, Dinnyes A, Kobolak J, Ferdinandy P, Gorbe A, Todorovic Z, Krstic D, Savic Vujovic K, Jovicic D, Basta Jovanovic G, Radojevic Skodric S, Prostran M, Dean S, Mee CJ, Harvey KL, Hussain A, Pena C, Paltineanu B, Voinea S, Revnic F, Ginghina C, Zaglia T, Ceriotti P, Campo A, Carullo P, Armani A, Coppini R, Vida V, Olivotto I, Stellin G, Rizzuto R, De Stefani D, Sandri M, Catalucci D, Mongillo M, Soumaka E, Kloukina I, Tsikitis M, Makridakis M, Varela A, Davos C, Vlachou A, Capetanaki Y, Iqbal MM, Bennett H, Davenport B, Pinali C, Cooper G, Cartwright E, Kitmitto A, Strutynska NA, Mys LA, Sagach VF, Franco A, Sorriento D, Trimarco B, Iaccarino G, Ciccarelli M, Verzijl A, Stam K, Van Duin R, Reiss IKM, Duncker DJ, Merkus D, Shakeri H, Orije M, Leloup AJ, Van Hove CE, Van Craenenbroeck EM, De Meyer GRY, Vrints CJ, Lemmens K, Desjardins-Creapeau L, Wu R, Lamarre-Cliche M, Larochelle P, Bherer L, Girouard H, Melenovsky M, Kvasilova A, Benes J, Ruskova K, Sedmera D, Ana Barral ABV, Martin Fernandez M, Pablo Roman Garcia PRG, Juan Carlos Llosa JCLL, Manuel Naves Diaz MND, Cesar Moris CM, Jorge B Cannata-Andia JBCA, Isabel Rodriguez IR, Voevoda M, Gromova E, Maximov V, Panov D, Gagulin I, Gafarova A, Palahniuk H, Pashkova IP, Zhebel NV, Starzhynska OL, Naidoo DP, Rawojc K, Enguita FJ, Grudzien G, Cordwell SJ, White MY, Massaro M, Scoditti E, Calabriso N, Pellegrino M, Martinelli R, Gatta V, De Caterina R, Nasibullin TR, Erdman VV, Tuktarova IA, Mustafina OE, Hyttinen J, Severi S, Vorobyov GG, Sagach VF, Batmyagmar KH, Lkhagvasuren Z, Gapon LI, Musikhina NA, Avdeeva KS, Dyachkov SM, Heinonen I, Van Kranenburg M, De Beer VJ, Octavia Y, Van Geuns RJ, Van Den Meiracker AH, Van Der Velden J, Merkus D, Duncker DJ, Everson FP, Ogundipe T, Grandjean T, De Boever P, Goswami N, Strijdom H, Suceveanu AI, Suceveanu AP, Mazilu L, Tofoleanu DE, Catrinoiu D, Rohla M, Hauser C, Huber K, Wojta H, Weiss TW, Melnikova MA, Olezov NV, Gimaev RH, Khalaf H, Ruzov VI, Adao R, Mendes-Ferreira P, Santos-Ribeiro D, Rademaker M, Leite-Moreira AF, Bras-Silva C, Alvarenga LAA, Falcao RSP, Dias RR, Lacchini S, Gutierrez PS, Michel JB, Gurfinkel YUI, Atkov OYU, Teichert M, Korn C, Mogler C, Hertel S, Arnold C, Korff T, Augustin HG, Van Duin RWB, De Wijs-Meijler DPM, Verzijl A, Duncker DJ, Merkus D, D'alessandra Y, Farina FM, Casella M, Catto V, Carbucicchio C, Dello Russso A, Stadiotti I, Brambilla S, Chiesa M, Giacca M, Colombo GI, Pompilio G, Tondo C, Ahlin F, Andric T, Tihanyi D, Wojta J, Huber K, O'connell E, Butt A, Murphy L, Pennington S, Ledwidge M, Mcdonald K, Baugh J, Watson C, Suades R, Crespo J, Estruch R, Badimon L, Dyachenko A, Ryabukho V, Evtushenko V, Saushkina YU, Lishmanov YU, Smyshlyaev K, Bykov A, Popov S, Pavlyukova E, Anfinogenova Y, Szigetfu E, Kapornai B, Forizs E, Jenei ZS, Nagy Z, Merkely B, Zima E, Cai A, Dworakowski R, Gibbs T, Piper S, Jegard N, Mcdonagh T, Gegenava M, Dementieva II, Morozov YUA, Barsanti C, Stea F, Lenzarini F, Kusmic C, Faita F, Halonen PJ, Puhakka PH, Hytonen JP, Taavitsainen JM, Yla-Herttuala S, Supit EA, Carr CA, Groenendijk BCW, Gorsse-Bakker C, Panasewicz A, Sneep S, Tempel D, Van Der Giessen WJ, Duncker DJ, Rys J, Daraio C, Dell'era P, Paloczi J, Pigler J, Eder A, Ferdinandy P, Eschenhagen T, Gorbe A, Mazo MM, Amdursky N, Peters NS, Stevens MM, Terracciano CM. Poster session 2Morphogenetic mechanisms290MiR-133 regulates retinoic acid pathway during early cardiac chamber specification291Bmp2 regulates atrial differentiation through miR-130 during early heart looping formationDevelopmental genetics294Association of deletion allele of insertion/deletion polymorphism in alpha 2B adrenoceptor gene and hypertension with or without type 2 diabetes mellitus295Association of G1359A polymorphism of the endocannabinoid type 1 receptor (CNR1) with coronary artery disease (CAD) with type 2 diabetes mellitusCell growth, differentiation and stem cells - Vascular298Gamma-secretase inhibitor prevents proliferation and migration of ductus arteriosus smooth muscle cells: a role of Notch signaling in postnatal closure of ductus arteriosus299Mesenchymal stromal-like cells (MLCs) derived from induced pluripotent stem (iPS) cells: a promising therapeutic option to promote neovascularization300Sonic Hedgehog promotes mesenchymal stem cell differentiation to vascular smooth muscle cells in cardiovacsular disease301Proinflammatory cytokine secretion and epigenetic modification in endothelial cells treated LPS-GinfivalisCell death and apoptosis - Vascular304Mitophagy acts as a safeguard mechanism against human vascular smooth muscle cell apoptosis induced by atherogenic lipidsTranscriptional control and RNA species - Vascular307MicroRNA-34a role in vascular calcification308Local delivery of a miR-146a inhibitor utilizing a clinically applicable approach attenuates neointima formation after vascular injury309Long noncoding RNA landscape of hypoxic endothelial cells310Specific circulating microRNAs levels associate with hypertension, hyperglycemia and dysfunctional HDL in acute coronary syndrome patientsCytokines and cellular inflammation - Vascular313Phosphodiesterase5A up-regulation in vascular endothelium under pro-inflammatory conditions: a newly disclosed anti-inflammatory activity for the omega-3polyunsaturated aatty acid docosahexaenoic acid314Cardiovascular risk modifying with extra-low dose anticytokine drugs in rhematoid arthritis315Conversion of human M-CSF macrophages into foam cells reduces their proinflammatory responses to classical M1-polarizing activation316Lymphocytic myocarditis coincides with increased plaque inflammation and plaque hemorrhage in coronary arteries, facilitating myocardial infarction317Serum osteoprotegerin level predictsdeclined numerous of circulating endothelial- derived and mononuclear-derived progenitor cells in patients with metabolic syndromeGrowth factors and neurohormones - Vascular320Effect of gastrin-releasing peptide (GRP) on vascular inflammationSignal transduction - Heart323A new synthetic peptide regulates hypertrophy in vitro through means of the inhibition of nfkb324Inducible fibroblast-specific knockout of p38 alpha map kinase is cardioprotective in a mouse model of isoproterenol-induced cardiac hypertrophy325Regulation of beta-adrenoceptor-evoked inotropic responses by inhibitory G protein, adenylyl cyclase isoforms 5 and 6 and phosphodiesterases326Binding to RGS3 and stimulation of M2 muscarinic acetylcholine receptors modulates the substrate specificity of p190RhoGAP in cardiac myocytes327Cardiac regulation of post-translational modifications, parylation and deacetylation in LMNA dilated cardiomyopathy mouse model328Beta-adrenergic regulation of the b56delta/pp2a holoenzyme in cardiac myocytes through b56delta phosphorylation at serine 573Nitric oxide and reactive oxygen species - Vascular331Oxidative stress-induced miR-200c disrupts the regulatory loop among SIRT1, FOXO1 and eNOS332Antioxidant therapy prevents oxidative stress-induced endothelial dysfunction and Enhances Wound Healing333Morphological and biochemical characterization of red blood cell in coronary artery diseaseCytoskeleton and mechanotransduction - Heart336Novel myosin activator, JSH compounds, increased myocardial contractility without chronotropic effect in ratsExtracellular matrix and fibrosis - Vascular339Ablation of Toll-like receptor 9 causes cardiac rupture after myocardial infarction by attenuating proliferation and differentiation of cardiac fibroblasts340Altered vascular remodeling in the mouse hind limb ischemia model in Factor VII activating protease (FSAP) deficiencyVasculogenesis, angiogenesis and arteriogenesis343Pro-angiogenic effects of proly-hydroxylase inhibitors and their potential for use in a novel strategy of therapeutic angiogenesis for coronary total occlusion344Nrf2 drives angiogenesis in transcription-independent manner: new function of the master regulator of oxidative stress response345Angiogenic gene therapy, despite efficient vascular growth, is not able to improve muscle function in normoxic or chronically ischemic rabbit hindlimbs -role of capillary arterialization and shunting346Effect of PAR-1 inhibition on collateral vessel growth in the murine hind limb model347Quaking is a key regulator of endothelial cell differentiation, neovascularization and angiogenesis348"Emerging angiogenesis" in the chick chorioallantoic membrane (CAM). An in vivo study349Exosomes from cardiomyocyte progenitor cells and mesenchymal stem cells stimulate angiogenesis in vitro and in vivo via EMMPRINEndothelium352Reciprocal regulation of GRK2 and bradykinin receptor stimulation modulate Ca2+ intracellular level in endothelial cells353The roles of bone morphogenetic proteins 9 and 10 in endothelial inflammation and atherosclerosis354The contribution of GPR55 to the L-alpha-lysophosphatidylinositol-induced vasorelaxation in isolated human pulmonary arteries355The endothelial protective ACE inhibitor Zofenoprilat exerts anti-inflammatory activities through H2S production356A new class of glycomimetic drugs to prevent free fatty acid-induced endothelial dysfunction357Endothelial progenitor cells to apoptotic endothelial cell-derived microparticles ration differentiatesas preserved from reduced ejection fractionheart failure358Proosteogenic genes are activated in endothelial cells of patients with thoracic aortic aneurysm359Endothelin ETB receptors mediate relaxing responses to insulin in pericardial resistance arteries from patients with cardiovascular disease (CVD)Smooth muscle and pericytes362CX3CR1 positive myeloid cells regulate vascular smooth muscle tone by inducing calcium oscillations via activation of IP3 receptors363A novel function of PI3Kg on cAMP regulation, role in arterial wall hyperplasia through modulation of smooth muscle cells proliferation364NRP1 and NRP2 play important roles in the development of neointimal hyperplasia in vivo365Azithromycin induces autophagy in aortic smooth muscle cellsCoagulation, thrombosis and platelets368The real time in vivo evaluation of platelet-dependent aldosterone prothrombotic action in mice369Development of a method for in vivo detection of active thrombi in mice370The antiplatelet effects of structural analogs of the taurine chloramine371The influence of heparin anticoagulant drugs on functional state of human platelets372Regulation of platelet aggregation and adenosine diphosphate release by d dimer in acute coronary syndrome (in vitro study)Oxygen sensing, ischaemia and reperfusion375Sirtuin 5 mediates brain injury in a mouse model of cerebral ischemia-reperfusion376Abscisic acid: a new player in cardiomyocyte protection from ischaemia?377Protective effects of ultramicronized palmitoylethanolamide (PEA-um) in myocardial ischaemia and reperfusion injury in vivo378Identification of stem cell-derived cardiomyocytes using cardiac specific markers and additional testing of these cells in simulated ischemia/reperfusion system379Single-dose intravenous metformin treatment could afford significant protection of the injured rat kidney in an experimental model of ischemia-reperfusion380Cardiotoxicity of long acting muscarinic receptor antagonists used for chronic obstructive pulmonary disease381Dependence antioxidant potential on the concentration of amino acids382The impact of ischemia-reperfusion on physiological parameters,apoptosis and ultrastructure of rabbit myocardium with experimental aterosclerosisMitochondria and energetics385MicroRNA-1 dependent regulation of mitochondrial calcium uniporter (MCU) in normal and hypertrophied hearts386Mitochondrial homeostasis and cardioprotection: common targets for desmin and aB-crystallin387Overexpression of mitofusin-2 (Mfn2) and associated mitochondrial dysfunction in the diabetic heart388NO-dependent prevention of permeability transition pore (MPTP) opening by H2S and its regulation of Ca2+ accumulation in rat heart mitochondria389G protein coupled receptor kinase 2 (GRK2) is fundamental in recovering mitochondrial morphology and function after exposure to ionizing radiation (IR)Gender issues392Sex differences in pulmonary vascular control; focus on the nitric oxide pathwayAging395Heart failure with preserved ejection fraction develops when feeding western diet to senescence-accelerated mice396Cardiovascular markers as predictors of cognitive decline in elderly hypertensive patients397Changes in connexin43 in old rats with volume overload chronic heart failureGenetics and epigenetics400Calcium content in the aortic valve is associated with 1G>2G matrix metalloproteinase 1 polymorphism401Neuropeptide receptor gene s (NPSR1) polymorphism and sleep disturbances402Endothelin-1 gene Lys198Asn polymorphism in men with essential hypertension complicated and uncomplicated with chronic heart failure403Association of common polymorphisms of the lipoprotein lipase and pon1 genes with the metabolic syndrome in a sample of community participantsGenomics, proteomics, metabolomics, lipidomics and glycomics405Gene expression quantification using multiplexed color-coded probe pairs to determine RNA content in sporadic cardiac myxoma406Large-scale phosphorylation study of the type 2 diabetic heart subjected to ischemia / reperfusion injury407Transcriptome-based identification of new anti-inflammatory properties of the olive oil hydroxytyrosol in vascular endothelial cell under basal and proinflammatory conditions408Gene polymorphisms combinations and risk of myocardial infarctionComputer modelling, bioinformatics and big data411Comparison of the repolarization reserve in three state-of-the-art models of the human ventricular action potentialMetabolism, diabetes mellitus and obesity414Endothelial monocyte-activating polypeptide-II improves heart function in type -I Diabetes mellitus415Admission glucose level is independent predictor of impaired left ventricular function in patients with acute myocardial infarction: a two dimensional speckle-tracking echocardiography study416Association between biochemical markers of lipid profile and inflammatory reaction and stiffness of the vascular wall in hypertensive patients with abdominal obesity417Multiple common co-morbidities produce left ventricular diastolic dysfunction associated with coronary microvascular dysfunction, oxidative stress and myocardial stiffening418Investigating the cardiovascular effects of antiretroviral drugs in a lean and high fat/sucrose diet rat model of obesity419Statins in the treatment of non-alcoholic steatohepatitis (NASH). Our experience from a 2-year prospective study in Constanta County, Romania420Epicardial adipose tissue as a predictor of cardiovascular outcome in patients with ACS undergoing PCI?Arterial and pulmonary hypertension423Dependence between heart rhythm disorers and ID polymorphism of ACE gene in hypertensive patients424Molecular mechanisms underlying the beneficial effects of Urocortin 2 in pulmonary arterial hypertension425Inhibition of TGf-b axis and action of renin-angiotensin system in human ascending aorta aneurysms426Early signs of microcirculation and macrocirculation abnormalities in prehypertension427Vascular smooth muscle cell-expressed Tie-2 controls vascular tone428Cardiac and vascular remodelling in the development of chronic thrombo-embolic pulmonary hypertension in a novel swine modelBiomarkers431Arrhythmogenic cardiomyopathy: a new, non invasive biomarker432Can circulating microRNAs distinguish type 1 and type 2 myocardial infarction?433Design of a high-throughput multiplex proteomics assay to identify left ventricular diastolic dysfunction in diabetes434Monocyte-derived and P-selectin-carrying microparticles are differently modified by a low fat diet in patients with cardiovascular risk factors who will and who will not develop a cardiovascular event435Red blood cell distribution width assessment by polychromatic interference microscopy of thin films in chronic heart failure436Invasive and noninvasive evaluation of quality of radiofrequency-induced cardiac denervation in patients with atrial fibrillation437The effect of therapeutic hypothermia on the level of brain derived neurotrophic factor (BDNF) in sera following cardiopulmonary resustitation438Novel biomarkers to predict outcome in patients with heart failure and severe aortic stenosis439Biological factors linking depression and anxiety to cardiovascular disease440Troponins and myoglobin dynamic at coronary arteries graftingInvasive, non-invasive and molecular imaging443Diet composition effects on the genetic typing of the mouse ob mutation: a micro-ultrasound characterization of cardiac function, macro and micro circulation and liver steatosis444Characterization of pig coronary and rabbit aortic lesions using IV-OCT quantitative analysis: correlations with histologyGene therapy and cell therapy447Enhancing the survival and angiogenic potential of mouse atrial mesenchymal cells448VCAM-1 expression in experimental myocardial infarction and its relation to bone marrow-derived mononuclear cell retentionTissue engineering451Advanced multi layered scaffold that increases the maturity of stem cell-derived human cardiomyocytes452Response of engineered heart tissue to simulated ischemia/reperfusion in the presence of acute hyperglycemic conditions453Serum albumin hydrogels prevent de-differentiation of neonatal cardiomyocytes454A novel paintbrush technique for transfer of low viscosity ultraviolet light curable cyan methacrylate on saline immersed in-vitro sheep heart. Cardiovasc Res 2016. [DOI: 10.1093/cvr/cvw149] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
37
|
Bianchessi V, Piacentini L, Chiesa M, Saporiti F, Colombo G, Pesce M, M.C.Vinci. Microarray analysis reveals distinct RNA expression profiles in endothelial progenitor cells exposed to pro-inflammatory environment or oxidized LDL. Vascul Pharmacol 2015. [DOI: 10.1016/j.vph.2015.11.008] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
38
|
Forte S, Nisati A, Passarino G, Tenchini R, Calame CMC, Chiesa M, Cobal M, Corcella G, Degrassi G, Ferrera G, Magnea L, Maltoni F, Montagna G, Nason P, Nicrosini O, Oleari C, Piccinini F, Riva F, Vicini A. The Standard Model from LHC to future colliders. Eur Phys J C Part Fields 2015; 75:554. [PMID: 26692817 PMCID: PMC4665931 DOI: 10.1140/epjc/s10052-015-3759-0] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 06/09/2015] [Accepted: 10/25/2015] [Indexed: 06/05/2023]
Abstract
This review summarizes the results of the activities which have taken place in 2014 within the Standard Model Working Group of the "What Next" Workshop organized by INFN, Italy. We present a framework, general questions, and some indications of possible answers on the main issue for Standard Model physics in the LHC era and in view of possible future accelerators.
Collapse
Affiliation(s)
- S. Forte
- />Dipartimento di Fisica, Università di Milano, Via Celoria 16, 20133 Milan, Italy
- />INFN, Sezione di Milano, Via Celoria 16, 20133 Milan, Italy
| | - A. Nisati
- />INFN, Sezione di Roma, Piazzale Aldo Moro 2, 00185 Rome, Italy
| | - G. Passarino
- />Dipartimento di Fisica, Università di Torino, Via P. Giuria 1, 10125 Turin, Italy
- />INFN, Sezione di Torino, Via P. Giuria 1, 10125 Turin, Italy
| | - R. Tenchini
- />INFN, Sezione di Pisa, Largo B. Pontecorvo 3, 56127 Pisa, Italy
| | | | - M. Chiesa
- />INFN, Sezione di Pavia, via Bassi 6, 27100 Pavia, Italy
| | - M. Cobal
- />Dipartimento di Chimica, Fisica e Ambiente, Università di Udine, Via delle Scienze, 206, 33100 Udine, Italy
- />INFN, Gruppo Collegato di Udine, Via delle Scienze, 206, 33100 Udine, Italy
| | - G. Corcella
- />INFN, Laboratori Nazionali di Frascati, Via E. Fermi 40, 00044 Frascati, Italy
| | - G. Degrassi
- />Dipartimento di Matematica e Fisica, Università’ Roma Tre, Via della Vasca Navale 84, 00146 Rome, Italy
- />INFN, Sezione di Roma Tre, Via della Vasca Navale 84, 00146 Rome, Italy
| | - G. Ferrera
- />Dipartimento di Fisica, Università di Milano, Via Celoria 16, 20133 Milan, Italy
- />INFN, Sezione di Milano, Via Celoria 16, 20133 Milan, Italy
| | - L. Magnea
- />Dipartimento di Fisica, Università di Torino, Via P. Giuria 1, 10125 Turin, Italy
- />INFN, Sezione di Torino, Via P. Giuria 1, 10125 Turin, Italy
| | - F. Maltoni
- />Centre for Cosmology, Particle Physics and Phenomenology (CP3), Université Catholique de Louvain, 1348 Louvain-la-Neuve, Belgium
| | - G. Montagna
- />Dipartimento di Fisica, Università di Pavia, via Bassi 6, 27100 Pavia, Italy
- />INFN, Sezione di Pavia, via Bassi 6, 27100 Pavia, Italy
| | - P. Nason
- />INFN, Sezione di Milano-Bicocca, Piazza della Scienza 3, 20126 Milan, Italy
| | - O. Nicrosini
- />INFN, Sezione di Pavia, via Bassi 6, 27100 Pavia, Italy
| | - C. Oleari
- />Dipartimento di Fisica, Università di Milano-Bicocca, Piazza della Scienza 3, 20126 Milan, Italy
- />INFN, Sezione di Milano-Bicocca, Piazza della Scienza 3, 20126 Milan, Italy
| | - F. Piccinini
- />INFN, Sezione di Pavia, via Bassi 6, 27100 Pavia, Italy
| | - F. Riva
- />Institut de Théorie des Phénoménes Physiques, École Polytechnique Fédérale de Lausanne, 1015 Lausanne, Switzerland
| | - A. Vicini
- />Dipartimento di Fisica, Università di Milano, Via Celoria 16, 20133 Milan, Italy
- />INFN, Sezione di Milano, Via Celoria 16, 20133 Milan, Italy
| |
Collapse
|
39
|
Sommariva E, Brambilla S, Carbucicchio C, Gambini E, Meraviglia V, Dello Russo A, Farina FM, Casella M, Catto V, Pontone G, Chiesa M, Stadiotti I, Cogliati E, Paolin A, Ouali Alami N, Preziuso C, d'Amati G, Colombo GI, Rossini A, Capogrossi MC, Tondo C, Pompilio G. Cardiac mesenchymal stromal cells are a source of adipocytes in arrhythmogenic cardiomyopathy. Eur Heart J 2015; 37:1835-46. [PMID: 26590176 PMCID: PMC4912024 DOI: 10.1093/eurheartj/ehv579] [Citation(s) in RCA: 63] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/20/2015] [Accepted: 10/07/2015] [Indexed: 01/21/2023] Open
Abstract
AIM Arrhythmogenic cardiomyopathy (ACM) is a genetic disorder mainly due to mutations in desmosomal genes, characterized by progressive fibro-adipose replacement of the myocardium, arrhythmias, and sudden death. It is still unclear which cell type is responsible for fibro-adipose substitution and which molecular mechanisms lead to this structural change. Cardiac mesenchymal stromal cells (C-MSC) are the most abundant cells in the heart, with propensity to differentiate into several cell types, including adipocytes, and their role in ACM is unknown. The aim of the present study was to investigate whether C-MSC contributed to excess adipocytes in patients with ACM. METHODS AND RESULTS We found that, in ACM patients' explanted heart sections, cells actively differentiating into adipocytes are of mesenchymal origin. Therefore, we isolated C-MSC from endomyocardial biopsies of ACM and from not affected by arrhythmogenic cardiomyopathy (NON-ACM) (control) patients. We found that both ACM and control C-MSC express desmosomal genes, with ACM C-MSC showing lower expression of plakophilin (PKP2) protein vs. CONTROLS Arrhythmogenic cardiomyopathy C-MSC cultured in adipogenic medium accumulated more lipid droplets than controls. Accordingly, the expression of adipogenic genes was higher in ACM vs. NON-ACM C-MSC, while expression of cell cycle and anti-adipogenic genes was lower. Both lipid accumulation and transcription reprogramming were dependent on PKP2 deficiency. CONCLUSIONS Cardiac mesenchymal stromal cells contribute to the adipogenic substitution observed in ACM patients' hearts. Moreover, C-MSC from ACM patients recapitulate the features of ACM adipogenesis, representing a novel, scalable, patient-specific in vitro tool for future mechanistic studies.
Collapse
Affiliation(s)
- E Sommariva
- Vascular Biology and Regenerative Medicine Unit, Centro Cardiologico Monzino IRCCS, via Parea 4, Milan 20138, Italy
| | - S Brambilla
- Vascular Biology and Regenerative Medicine Unit, Centro Cardiologico Monzino IRCCS, via Parea 4, Milan 20138, Italy
| | - C Carbucicchio
- Cardiac Arrhythmia Research Centre, Centro Cardiologico Monzino IRCCS, Milan, Italy
| | - E Gambini
- Vascular Biology and Regenerative Medicine Unit, Centro Cardiologico Monzino IRCCS, via Parea 4, Milan 20138, Italy
| | - V Meraviglia
- Center for Biomedicine, European Academy Bozen/Bolzano (EURAC), Bolzano, Italy - Affiliated Institute of the University of Lübeck, Lübeck, Germany
| | - A Dello Russo
- Cardiac Arrhythmia Research Centre, Centro Cardiologico Monzino IRCCS, Milan, Italy
| | - F M Farina
- Vascular Biology and Regenerative Medicine Unit, Centro Cardiologico Monzino IRCCS, via Parea 4, Milan 20138, Italy
| | - M Casella
- Cardiac Arrhythmia Research Centre, Centro Cardiologico Monzino IRCCS, Milan, Italy
| | - V Catto
- Cardiac Arrhythmia Research Centre, Centro Cardiologico Monzino IRCCS, Milan, Italy
| | - G Pontone
- Department of Cardiovascular Imaging, Centro Cardiologico Monzino IRCCS, Milan, Italy
| | - M Chiesa
- Immunology and Functional Genomics Unit, Centro Cardiologico Monzino IRCCS, Milan, Italy Electrical Computer and Biomedical Engineering, Università degli Studi di Pavia, Pavia, Italy
| | - I Stadiotti
- Vascular Biology and Regenerative Medicine Unit, Centro Cardiologico Monzino IRCCS, via Parea 4, Milan 20138, Italy
| | - E Cogliati
- Tissue Bank of Veneto Region, Ca' Foncello Hospital, Treviso, Italy
| | - A Paolin
- Tissue Bank of Veneto Region, Ca' Foncello Hospital, Treviso, Italy
| | - N Ouali Alami
- Vascular Biology and Regenerative Medicine Unit, Centro Cardiologico Monzino IRCCS, via Parea 4, Milan 20138, Italy
| | - C Preziuso
- Department of Radiological, Oncological and Pathologic Sciences, La Sapienza University, Rome, Italy
| | - G d'Amati
- Department of Radiological, Oncological and Pathologic Sciences, La Sapienza University, Rome, Italy
| | - G I Colombo
- Immunology and Functional Genomics Unit, Centro Cardiologico Monzino IRCCS, Milan, Italy
| | - A Rossini
- Center for Biomedicine, European Academy Bozen/Bolzano (EURAC), Bolzano, Italy - Affiliated Institute of the University of Lübeck, Lübeck, Germany
| | - M C Capogrossi
- Laboratory of Vascular Pathology, Istituto Dermopatico dell'Immacolata IRCCS, Rome, Italy
| | - C Tondo
- Cardiac Arrhythmia Research Centre, Centro Cardiologico Monzino IRCCS, Milan, Italy
| | - G Pompilio
- Vascular Biology and Regenerative Medicine Unit, Centro Cardiologico Monzino IRCCS, via Parea 4, Milan 20138, Italy Department of Clinical Sciences and Community Health, Università degli Studi di Milano, Milan, Italy
| |
Collapse
|
40
|
Alio del Barrio JL, Chiesa M, Garagorri N, Garcia-Urquia N, Fernandez-Delgado J, Bataille L, Rodriguez A, Arnalich-Montiel F, Zarnowski T, Álvarez de Toledo JP, Alio JL, De Miguel MP. Acellular human corneal matrix sheets seeded with human adipose-derived mesenchymal stem cells integrate functionally in an experimental animal model. Exp Eye Res 2015; 132:91-100. [DOI: 10.1016/j.exer.2015.01.020] [Citation(s) in RCA: 48] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/20/2014] [Revised: 06/04/2014] [Accepted: 01/23/2015] [Indexed: 02/07/2023]
|
41
|
Morra E, Maurelli S, Chiesa M, Van Doorslaer S. Probing the coordination environment of Ti3+ ions coordinated to nitrogen-containing Lewis bases. Phys Chem Chem Phys 2015. [DOI: 10.1039/c5cp03417e] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
A combined EPR and DFT study on model systems reveals fingerprint 14N hyperfine and quadrupole data to identify binding of nitrogen-containing Lewis bases to Ti(iii).
Collapse
Affiliation(s)
- E. Morra
- Dipartimento di Chimica
- University of Torino Via Giuria
- 7-10125 Torino
- Italy
- University of Antwerp
| | - S. Maurelli
- Dipartimento di Chimica
- University of Torino Via Giuria
- 7-10125 Torino
- Italy
| | - M. Chiesa
- Dipartimento di Chimica
- University of Torino Via Giuria
- 7-10125 Torino
- Italy
| | | |
Collapse
|
42
|
Donzelli M, Busini L, Chiesa M, Ganoth D, Hershko A, Draetta GF. Hierarchical order of phosphorylation events commits Cdc25A to Beta-TrCP-dependent degradation. Cell Cycle 2014. [DOI: 10.4161/cc.3.4.770] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022] Open
|
43
|
Alió del Barrio JL, Chiesa M, Gallego Ferrer G, Garagorri N, Briz N, Fernandez-Delgado J, Sancho-Tello Valls M, Botella CC, García-Tuñón I, Bataille L, Rodriguez A, Arnalich-Montiel F, Gómez Ribelles JL, Antolinos-Turpín CM, Gómez-Tejedor JA, Alió JL, De Miguel MP. Biointegration of corneal macroporous membranes based on poly(ethyl acrylate) copolymers in an experimental animal model. J Biomed Mater Res A 2014; 103:1106-18. [DOI: 10.1002/jbm.a.35249] [Citation(s) in RCA: 26] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/19/2014] [Revised: 05/26/2014] [Accepted: 06/02/2014] [Indexed: 11/07/2022]
Affiliation(s)
| | - Massimo Chiesa
- Cell Engineering Laboratory, IdiPAZ, La Paz Hospital Research Institute; Madrid' 28046 Spain
| | - Gloria Gallego Ferrer
- Center for Biomaterials and Tissue Engineering, Polytechnic University of Valencia; 46022 Valencia Spain
- CIBER de Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN); Spain
| | - Nerea Garagorri
- CIBER de Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN); Spain
- Tecnalia Research and Innovation, Health Division-Biomaterials Area; Mikeletegi Pasealekua 2 20009 Donostia-San Sebastian Spain
| | - Nerea Briz
- CIBER de Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN); Spain
- Tecnalia Research and Innovation, Health Division-Biomaterials Area; Mikeletegi Pasealekua 2 20009 Donostia-San Sebastian Spain
| | - Jorge Fernandez-Delgado
- Department of Plastic and Reconstructive Surgery; Santa Cristina Hospital and Centrocim; Madrid Spain
| | - Maria Sancho-Tello Valls
- Pathology Department, Medicine and Odontology Faculty, Valencia University; 46022 Valencia Spain
| | - Carmen Carda Botella
- Pathology Department, Medicine and Odontology Faculty, Valencia University; 46022 Valencia Spain
| | - Ignacio García-Tuñón
- Cell Engineering Laboratory, IdiPAZ, La Paz Hospital Research Institute; Madrid' 28046 Spain
| | - Laurent Bataille
- Vissum Ophthalmological Institute and Miguel Hernandez University; Alicante Spain
| | - Alejandra Rodriguez
- Vissum Ophthalmological Institute and Miguel Hernandez University; Alicante Spain
| | | | - Jose L. Gómez Ribelles
- Center for Biomaterials and Tissue Engineering, Polytechnic University of Valencia; 46022 Valencia Spain
- CIBER de Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN); Spain
| | - Carmen M. Antolinos-Turpín
- Center for Biomaterials and Tissue Engineering, Polytechnic University of Valencia; 46022 Valencia Spain
| | - Jose A. Gómez-Tejedor
- Center for Biomaterials and Tissue Engineering, Polytechnic University of Valencia; 46022 Valencia Spain
| | - Jorge L. Alió
- Vissum Ophthalmological Institute and Miguel Hernandez University; Alicante Spain
| | - Maria P. De Miguel
- Cell Engineering Laboratory, IdiPAZ, La Paz Hospital Research Institute; Madrid' 28046 Spain
| |
Collapse
|
44
|
Diamanti M, Souier T, Stefancich M, Chiesa M, Pedeferri M. Probing anodic oxidation kinetics and nanoscale heterogeneity within TiO2 films by Conductive Atomic Force Microscopy and combined techniques. Electrochim Acta 2014. [DOI: 10.1016/j.electacta.2014.02.098] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
45
|
Blazquez-Martinez A, Chiesa M, Arnalich F, Fernandez-Delgado J, Nistal M, De Miguel MP. c-Kit identifies a subpopulation of mesenchymal stem cells in adipose tissue with higher telomerase expression and differentiation potential. Differentiation 2014; 87:147-60. [PMID: 24713343 DOI: 10.1016/j.diff.2014.02.007] [Citation(s) in RCA: 21] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/26/2013] [Revised: 01/24/2014] [Accepted: 02/24/2014] [Indexed: 12/14/2022]
Abstract
The stromal vascular fraction (SVF) of adipose tissue is an easy to obtain source of adipose tissue-derived stem cells (ADSCs). We and others have achieved significant but suboptimal therapeutic effects with ADSCs in various settings, mainly due to low rates of differentiation into specific cell types and with the downside of undesired side effects as a consequence of the undifferentiated ADSCs. These data prompted us to find new stem cell-specific markers for ADSCs and/or subpopulations with higher differentiation potential to specific lineages. We found a subpopulation of human ADSCs, marked by c-Kit positiveness, resides in a perivascular location, and shows higher proliferative activity and self-renewal capacity, higher telomerase activity and expression, higher in vitro adipogenic efficiency, a higher capacity for the maintenance of cardiac progenitors, and higher pancreatogenic and hepatogenic efficiency independently of CD105 expression. Our data suggests that the isolation of ADSC subpopulations with anti-c-Kit antibodies allows for the selection of a more homogeneous subpopulation with increased cardioprotective properties and increased adipogenic and endodermal differentiation potential, providing a useful tool for specific therapies in regenerative medicine applications.
Collapse
Affiliation(s)
- A Blazquez-Martinez
- Cell Engineering Laboratory, La Paz University Hospital Research Institute, Madrid, Spain
| | - M Chiesa
- Cell Engineering Laboratory, La Paz University Hospital Research Institute, Madrid, Spain
| | - F Arnalich
- Department of Internal Medicine, La Paz University Hospital, Madrid, Spain
| | - J Fernandez-Delgado
- Department of Plastic and Reconstructive Surgery, Santa Cristina Hospital, and Centrocim, Madrid, Spain
| | - M Nistal
- Department of Pathology, La Paz University Hospital, Madrid, Spain
| | - M P De Miguel
- Cell Engineering Laboratory, La Paz University Hospital Research Institute, Madrid, Spain.
| |
Collapse
|
46
|
Maragliano C, Lilliu S, Dahlem MS, Chiesa M, Souier T, Stefancich M. Quantifying charge carrier concentration in ZnO thin films by Scanning Kelvin Probe Microscopy. Sci Rep 2014; 4:4203. [PMID: 24569599 PMCID: PMC3935190 DOI: 10.1038/srep04203] [Citation(s) in RCA: 33] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/05/2013] [Accepted: 02/10/2014] [Indexed: 11/10/2022] Open
Abstract
In the last years there has been a renewed interest for zinc oxide semiconductor, mainly triggered by its prospects in optoelectronic applications. In particular, zinc oxide thin films are being widely used for photovoltaic applications, in which the determination of the electrical conductivity is of great importance. Being an intrinsically doped material, the quantification of its doping concentration has always been challenging. Here we show how to probe the charge carrier density of zinc oxide thin films by Scanning Kelvin Probe Microscopy, a technique that allows measuring the contact potential difference between the tip and the sample surface with high spatial resolution. A simple electronic energy model is used for correlating the contact potential difference with the doping concentration in the material. Limitations of this technique are discussed in details and some experimental solutions are proposed. Two-dimensional doping concentration images acquired on radio frequency-sputtered intrinsic zinc oxide thin films with different thickness and deposited under different conditions are reported. We show that results inferred with this technique are in accordance with carrier concentration expected for zinc oxide thin films deposited under different conditions and obtained from resistivity and mobility measurements.
Collapse
Affiliation(s)
- C Maragliano
- Institute Center for Energy (iEnergy), Masdar Institute of Science and Technology, Abu Dhabi, UAE
| | - S Lilliu
- Institute Center for Microsystems (iMicro), Masdar Institute of Science and Technology, Abu Dhabi, UAE
| | - M S Dahlem
- Institute Center for Microsystems (iMicro), Masdar Institute of Science and Technology, Abu Dhabi, UAE
| | - M Chiesa
- Institute Center for Energy (iEnergy), Masdar Institute of Science and Technology, Abu Dhabi, UAE
| | - T Souier
- Institute Center for Energy (iEnergy), Masdar Institute of Science and Technology, Abu Dhabi, UAE
| | - M Stefancich
- Institute Center for Energy (iEnergy), Masdar Institute of Science and Technology, Abu Dhabi, UAE
| |
Collapse
|
47
|
Lilliu S, Maragliano C, Hampton M, Elliott M, Stefancich M, Chiesa M, Dahlem MS, Macdonald JE. EFM data mapped into 2D images of tip-sample contact potential difference and capacitance second derivative. Sci Rep 2013; 3:3352. [PMID: 24284731 PMCID: PMC3842085 DOI: 10.1038/srep03352] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/23/2013] [Accepted: 11/08/2013] [Indexed: 11/09/2022] Open
Abstract
We report a simple technique for mapping Electrostatic Force Microscopy (EFM) bias sweep data into 2D images. The method allows simultaneous probing, in the same scanning area, of the contact potential difference and the second derivative of the capacitance between tip and sample, along with the height information. The only required equipment consists of a microscope with lift-mode EFM capable of phase shift detection. We designate this approach as Scanning Probe Potential Electrostatic Force Microscopy (SPP-EFM). An open-source MATLAB Graphical User Interface (GUI) for images acquisition, processing and analysis has been developed. The technique is tested with Indium Tin Oxide (ITO) and with poly(3-hexylthiophene) (P3HT) nanowires for organic transistor applications.
Collapse
Affiliation(s)
- S Lilliu
- 1] School of Physics and Astronomy, Cardiff University, Queens Buildings, The Parade, Cardiff CF243AA, United Kingdom [2] Masdar Institute of Science and Technology, PO Box 54224, Abu Dhabi, United Arab Emirates
| | | | | | | | | | | | | | | |
Collapse
|
48
|
Diamanti MV, Gadelrab KR, Pedeferri MP, Stefancich M, Pehkonen SO, Chiesa M. Nanoscale investigation of photoinduced hydrophilicity variations in anatase and rutile nanopowders. Langmuir 2013; 29:14512-14518. [PMID: 24152147 DOI: 10.1021/la4034723] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/02/2023]
Abstract
The photoactive properties of TiO2 are employed to develop surfaces with self-cleaning capabilities. Clearly, the fine-tuning of such surfaces for different applications relies on a holistic understanding of the different aspects that induce the self-cleaning behavior. Among those, the mechanisms responsible for the photoinduced surface alteration in the TiO2 allotropes are still not completely understood. In this study, TiO2 polymorphs nanopowders are investigated by combining the high spatial resolution observables of recently developed atomic force microscopy (AFM) based force spectroscopy techniques with diffuse reflection infrared Fourier transform spectroscopy (DRIFTS). Phase maps under irradiated and nonirradiated conditions for anatase and rutile suggest the existence of two distinct behaviors that are further discerned by energy analysis of amplitude and phase vs distance curves. Independently, surface analysis of anatase and rutile by means of DRIFTS spectroscopy reveals a readily distinguishable coexistence of dissociated water and molecular water on the two phases, confirming the stronger photoactivity of anatase. The peculiarity of the surface interaction under UV exposure is further investigated by reconstructing the force profiles between the oscillating AFM tip and the TiO2 phases with the attempt of gaining a better understanding of the mechanisms that cause the different hydrophilic properties in the TiO2 allotropes.
Collapse
Affiliation(s)
- M V Diamanti
- Department of Chemistry, Materials and Chemical Engineering "G. Natta", Politecnico di Milano , Via Mancinelli 7, 20131 Milan, Italy
| | | | | | | | | | | |
Collapse
|
49
|
Maragliano C, Heskes D, Stefancich M, Chiesa M, Souier T. Dynamic electrostatic force microscopy technique for the study of electrical properties with improved spatial resolution. Nanotechnology 2013; 24:225703. [PMID: 23635384 DOI: 10.1088/0957-4484/24/22/225703] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/02/2023]
Abstract
The need to resolve the electrical properties of confined structures (CNTs, quantum dots, nanorods, etc) is becoming increasingly important in the field of electronic and optoelectronic devices. Here we propose an approach based on amplitude modulated electrostatic force microscopy to obtain measurements at small tip-sample distances, where highly nonlinear forces are present. We discuss how this improves the lateral resolution of the technique and allows probing of the electrical and surface properties. The complete force field at different tip biases is employed to derive the local work function difference. Then, by appropriately biasing the tip-sample system, short-range forces are reconstructed. The short-range component is then separated from the generic tip-sample force in order to recover the pure electrostatic contribution. This data can be employed to derive the tip-sample capacitance curve and the sample dielectric constant. After presenting a theoretical model that justifies the need for probing the electrical properties of the sample in the vicinity of the surface, the methodology is presented in detail and verified experimentally.
Collapse
Affiliation(s)
- C Maragliano
- Laboratory for Energy and Nano-sciences, Masdar Institute of Science and Technology, Abu Dhabi, United Arab Emirates.
| | | | | | | | | |
Collapse
|
50
|
Nespoli P, Parlatano D, Cortese G, Messore B, Bena C, Chiesa M, Veltri A. 201 CT findings in cystic fibrosis diagnosed in adulthood. J Cyst Fibros 2013. [DOI: 10.1016/s1569-1993(13)60342-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|